Source: http://www.patentgenius.com/patent/8135465.html
Timestamp: 2018-11-20 07:20:34
Document Index: 790875190

Matched Legal Cases: ['art 2', 'art 115', 'art 115', 'art 115', 'art 115', 'art115', 'art 115', 'art 115', 'art 115', 'art 115', 'art 115', 'art 115', 'art 115', 'art 115', 'art 115', 'art 115', 'art 115']

System providing ventricular pacing and biventricular coordination - Patent # 8135465 - PatentGenius
8135465 System providing ventricular pacing and biventricular coordination
Inventor: Krig, et al.
Application: 12/325,887
Inventors: Krig; David B. (Minneapolis, MN)
Stahl; Wyatt (Vadnais Heights, MN)
Foreign Patent Documents: 0033418; 0360412; 0401962; 0597459; 0617980; 744190; 0748638; 07-072910; WO-93/02746; WO-95/09029; WO-97/11745; WO 97/39798; WO-98/48891; WO-00/04950; WO-00/09206; WO-00/38782; WO-00/71200; WO-00/71202; WO-00/71203
"U.S. Appl. No. 10/852,602, Notice of Allowance mailed Aug. 4, 2008", 4 pgs. cited by other.
"U.S. Appl. No. 10/852,602, Amendment and Response filed Dec. 22, 2006 to Non-Final Office Action mailed Dec. 24, 2006", 20 pgs. cited by other.
"U.S. Appl. No. 10/852,602, Non-Final Office Action mailed Mar. 9, 2006", 6 pgs. cited by other.
"U.S. Appl. No. 10/852,602, Non-Final Office Action mailed Aug. 24, 2006", 7 pgs. cited by other.
"U.S. Appl. No. 10/852,602, Notice of Allowance mailed Jul. 11, 2007", 9 pgs. cited by other.
"U.S. Appl. No. 10/852,602, Notice of Allowance mailed Nov. 1, 2007", 4 pgs. cited by other.
"U.S. Appl. No. 10/852,602, Response filed Jun. 9, 2006 to Non-Final Office Action mailed Mar. 9, 2006", 23 pgs. cited by other.
"U.S. Appl. No. 10/852,602, Response filed Dec. 30, 2005 to Restriction Requirement mailed Nov. 30, 2005", 18 pgs. cited by other.
"U.S. Appl. No. 10/852,602, Restriction Requirement mailed Nov. 30, 2005", 4 pgs. cited by other.
"Pacemaker System Guide for PULSAR MAX II; Multiprogrammable Pacemakers", Product brochure published by Guidant Corporation, (Apr. 18, 1999), pp. 6-39-6-51. cited by other.
"Vitatron Medical Harmony Automatic Dual Chamber Pacemaker Product Information and Programming Guide", Viatron Medical, 22 pgs., (Date Unknown), Harmony Dual Chamber mentioned in publication Clinica, 467, p. 16, Sep. 11, 1991, "Rate Devices ImpactPacemaker Market", also mentioned in Clinica, 417, p. 9, Sep. 5, 1990 "French CNH Equipment Approvals"., Product Brochure published by Vitatron Medical, 22 pgs. cited by other.
Ayers, G. M., et al., "Ventricular Proarrhythmic Effects of Ventricular Cycle Length and Shock Strength in a Sheep Model of Transvenous Atrial Defibrillation", Circulation, 89 (1), (Jan. 1994), 413-422. cited by other.
Blommaert, D., et al., "Effective Prevention of Atrial Fibrillation by Continuous Atrial Overdrive Pacing After Coronary Artery Bypass Surgery", JACC, 35(6), (May 2000), 1411-1415. cited by other.
Clark, D. M., et al., "Hemodynamic Effects of an Irregular Sequence of Ventricular Cycle Lengths During Atrial Fibrillation", JACC, vol. 30, No. 4, (Oct. 1997), 1039-1045. cited by other.
Cohen, R. J., et al., "Quantitative Model for Ventricular Response During Atrial Fibrillation", IEEE Transactions on Biomedical Engineering, 30, (1983), 769-782. cited by other.
Duckers, H. J., et al., "Effective use of a novel rate-smoothing algorithm in atrial fibrillation by ventricular pacing", European Heart Journal, 18, (1997), 1951-1955. cited by other.
Fromer, M., et al., "Algorithm for the Prevention of Ventricular Tachycardia Onset: The Prevent Study", The American Journal of Cardiology, 83 (5B), (Mar. 11, 1999), pp. 45D-47D. cited by other.
Greenhut, S., et al., "Effectiveness of a Ventricular Rate Stabilization Algorithm During Atrial Fibrillation in Dogs", Pace Abstract, Abstract No. 60, (1996), 1 pg. cited by other.
Heuer, H., et al., "Dynamic Dual-Chamber Overdrive Pacing with an Implantable Pacemaker System: A New Method for Terminating Slow Ventricular Tachycardia", Zeitschrift fur Kardiologie, 75, German Translation by the Ralph McElroy Translation Company,Austin, TX, (1986), 6 pgs. cited by other.
Heuer, H., et al., "Dynamische Zweikammer-Overdrive-Stimulation mit einem implantierbaren Schrittmachersystem als neue Methode zur Beendigung Langsamer ventrikularer Tachykardien", Z Kardiol; 75, Includes English translation (5 pgs.), (1986),673-675. cited by other.
Jung, J., et al., "Discrimination of Sinus Rhythm, Atrial Flutter, and Atrial Fibrillation Using Bipolar Endocardial Signals", Journal of Cardiovascular Electrophysiology, 9 (7), (Jul. 1998), 689-695. cited by other.
Krig, David B., "Method and Apparatus for Treating Irregular Ventricular Contractions Such As During Atrial Arrhythmia", U.S. Appl. No. 10/643,590, filed Aug. 19, 2003, 45 pgs. cited by other.
Lau, C. P., et al., "A new pacing method for rapid regularization and rate control in atrial fibrillation", Am J Cardiol., 65(18), (May 15, 1990), 1198-1203. cited by other.
Lovett, E. G., et al., "Cardiac Pacing System for Prevention of Ventricular Fibrillation and Ventricular Tachycardia Episode", U.S. Appl. No. 12/816,088, filed Jun. 15, 2010, 31 pgs. cited by other.
Marcovecchio, A. F., et al., "Method for Delivering Atrial Defibbillation Therapy", U.S. Appl. No. 10/734,737, filed Dec. 12, 2003, 16 pgs. cited by other.
Mower, Morton, , U.S. Patent Office Patent Application Information Retrieval (PAIR) search results for U.S. Appl. No. 10/214,474, filed on Aug. 8, 2002, entitled "Method and Apparatus for Treating Hemodynamic Disfunction", 3 pgs. cited by other.
Seim, G., et al., "Classification of Atrial Flutter and Atrial Fibrillation Using an Atrial Dispersion Index (ADI)", Guidant CRM Therapy Research Peer Review Report Revision 2.0, (Jan. 6, 1999), 27 pgs. cited by other.
St. Jude Medical, "Atlas + HF Models V-343, V-341", User's Manual, Implantable Cardioverter-Defibrillator, (Sep. 2003), 1-30. cited by other.
Sweeney, M. O., et al., "Adverse Effect of Ventricular Pacing on Heart Failure and Atrial Fibrillation Among Patients With Normal Baseline QRS Duration in a Clinical Trial of Pacemaker Therapy for Sinus Node Dysfunction", Circulation, 107(23), (Jun.17, 2003), 2932-2937. cited by other.
Tse, H. F., et al., "Effects of ventricular rate regularization pacing on quality of life and symptoms in patients with atrial fibrillation (Atrial fibrillation symptoms mediated by pacing to mean rates [AF SYMPTOMS study])", Am J Cardiol., 94(7),(Oct. 2004), 938-941. cited by other.
Wittkampf, F. H. M., et al., "Rate Stabilization by Right Ventricular Pacing in Patients with Atrial Fibrillation", Pacing and Clinical Electrophysiology, 9(6, Part 2), (Nov.-Dec. 1986), 1147-1153. cited by other.
"U.S. Appl. No. 11/423,516, Final Office Action mailed Jun. 15, 2011", 5 pgs. cited by other.
"U.S. Appl. No. 11/423,516, Notice of Allowance mailed Sep. 12, 2011", 5 pgs. cited by other.
"U.S. Appl. No. 11/423,516, Response filed Aug. 10, 2011 to Final Office Action mailed Jun. 15, 2011", 7 pgs. cited by other.
"U.S. Appl. No. 09/316,515, Final Office Action mailed Mar. 2, 2001", 7 pgs. cited by other.
"U.S. Appl. No. 09/316,515, Final Office Action mailed Jul. 23, 2001", 7 pgs. cited by other.
"U.S. Appl. No. 09/316,515, Final Office Action mailed Jul. 29, 2003", 6 pgs. cited by other.
"U.S. Appl. No. 09/316,515, Final Office Action mailed Aug. 8, 2002", 8 pgs. cited by other.
"U.S. Appl. No. 09/316,515, Non Final Office Action mailed Feb. 12, 2003", 7 pgs. cited by other.
"U.S. Appl. No. 09/316,515, Non Final Office Action mailed Feb. 28, 2002", 11 pgs. cited by other.
"U.S. Appl. No. 09/316,515, Non Final Office Action mailed Mar. 1, 2004", 8 pgs. cited by other.
"U.S. Appl. No. 09/316,515, Non Final Office Action mailed Aug. 30, 2000", 7 pgs. cited by other.
"U.S. Appl. No. 09/316,515, Notice of Allowance mailed Aug. 12, 2003", 7 pgs. cited by other.
"U.S. Appl. No. 09/316,515, Notice of Allowance mailed Sep. 23, 2004", 8 pgs. cited by other.
"U.S. Appl. No. 09/316,515, Response filed Jan. 30, 2001 to Non Final Office Action mailed Aug. 30, 2000", 20 pgs. cited by other.
"U.S. Appl. No. 09/316,515, Response filed May 6, 2003 to Non Final Office Action mailed Feb. 12, 2003", 19 pgs. cited by other.
"U.S. Appl. No. 09/316,515, Response filed May 28, 2002 to Non Final Office Action mailed Feb. 28, 2002", 6 pgs. cited by other.
"U.S. Appl. No. 09/316,515, Response filed Jun. 7, 2001 to Final Office Action mailed Mar. 2, 2001", 8 pgs. cited by other.
"U.S. Appl. No. 09/316,515, Response filed Jun. 30, 2004 to Non Final Office Action mailed Mar. 1, 2004", 19 pgs. cited by other.
"U.S. Appl. No. 09/316,515, Response filed Nov. 6, 2001 to Final Office Action mailed Jul. 23, 2001", 6 pgs. cited by other.
"U.S. Appl. No. 09/316,515, Response filed Dec. 9, 2002 to Final Office Action mailed Aug. 8, 2002", 8 pgs. cited by other.
"U.S. Appl. No. 09/316,588, Non Final Office Action mailed Nov. 21, 2000", 4 pgs. cited by other.
"U.S. Appl. No. 09/316,588, Notice of Allowance mailed Mar. 19, 2001", 5 pgs. cited by other.
"U.S. Appl. No. 09/316,588, Response filed Feb. 21, 2001 to Non Final Office Action mailed Nov. 21, 2000", 10 pgs. cited by other.
"U.S. Appl. No. 09/316,682, Non Final Office Action mailed Jan. 19, 2001", 3 pgs. cited by other.
"U.S. Appl. No. 09/316,682, Notice of Allowance mailed May 11, 2001", 3 pgs. cited by other.
"U.S. Appl. No. 09/316,682, Notice of Allowance mailed Aug. 9, 2001", 3 pgs. cited by other.
"U.S. Appl. No. 09/316,682, Response filed Apr. 12, 2001 to Non Final Office Action mailed Jan. 19, 2001", 6 pgs. cited by other.
"U.S. Appl. No. 09/316,682, Response filed Oct. 20, 2000 to Restriction Requirement mailed Sep. 20, 2000", 1 pg. cited by other.
"U.S. Appl. No. 09/316,682, Restriction Requirement mailed Sep. 20, 2000", 5 pgs. cited by other.
"U.S. Appl. No. 09/316,741, Advisory Action mailed Jun. 6, 2001", 1 pg. cited by other.
"U.S. Appl. No. 09/316,741, Final Office Action mailed Mar. 26, 2001", 7 pgs. cited by other.
"U.S. Appl. No. 09/316,741, Non Final Office Action mailed Jul. 24, 2001", 6 pgs. cited by other.
"U.S. Appl. No. 09/316,741, Non Final Office Action mailed Aug. 30, 2000", 7 pgs. cited by other.
"U.S. Appl. No. 09/316,741, Notice of Allowance mailed Feb. 27, 2002", 4 pgs. cited by other.
"U.S. Appl. No. 09/316,741, Response filed Jan. 30, 2001 to Non Final Office Action mailed Aug. 30, 2000", 11 pgs. cited by other.
"U.S. Appl. No. 09/316,741, Response filed May 4, 2001 to Final Office Action mailed Mar. 26, 2001", 4 pgs. cited by other.
"U.S. Appl. No. 09/316,741, Response filed Oct. 24, 2001 to Non Final Office Action mailed Jul. 24, 2001", 9 pgs. cited by other.
"U.S. Appl. No. 09/569,295, Advisory Action mailed Nov. 30, 2004", 2 pgs. cited by other.
"U.S. Appl. No. 09/569,295, Corrected Notice of Allowability mailed Nov. 17, 2005", 2 pgs. cited by other.
"U.S. Appl. No. 09/569,295, Final Office Action Mailed Jan. 30, 2004'", 6 pgs. cited by other.
"U.S. Appl. No. 09/569,295, Final Office Action mailed Jul. 30, 2004", 7 pgs. cited by other.
"U.S. Appl. No. 09/569,295, Non Final Office Action mailed Apr. 10, 2003", 11 pgs. cited by other.
"U.S. Appl. No. 09/569,295, Non Final Office Action mailed Oct. 23, 2002", 8 pgs. cited by other.
"U.S. Appl. No. 09/569,295, Notice of Allowance mailed Jul. 5, 2005", 4 pgs. cited by other.
"U.S. Appl. No. 09/569,295, Notice of Allowance mailed Aug. 25, 2005", 4 pgs. cited by other.
"U.S. Appl. No. 09/569,295, Notice of Allowance mailed Nov. 29, 2005", 4 pgs. cited by other.
"U.S. Appl. No. 09/569,295, Response filed Jan. 23, 2003 to Non Final Office Action mailed Oct. 23, 2002", 9 pgs. cited by other.
"U.S. Appl. No. 09/569,295, Response filed Apr. 22, 2005 to Restriction Requirement mailed Mar. 23, 2005", 6 pgs. cited by other.
"U.S. Appl. No. 09/569,295, Response filed Jul. 10, 2003 to Non Final Office Action mailed Apr. 10, 2003", 9 pgs. cited by other.
"U.S. Appl. No. 09/569,295, Response filed Jul. 30, 2004 to Final Office Action Mailed Jul. 27, 2004", 10 pgs. cited by other.
"U.S. Appl. No. 09/569,295, Response filed Nov. 6, 2003 to Restriction Requirement mailed Oct. 6, 2003", 3 pgs. cited by other.
"U.S. Appl. No. 09/569,295, Restriction Requirement mailed Mar. 23, 2005", 4 pgs. cited by other.
"U.S. Appl. No. 09/569,295, Restriction Requirement mailed Oct. 6, 2003", 4 pgs. cited by other.
"U.S. Appl. No. 09/579,951, 312 Amendment filed Oct. 10, 2002", 2 pgs. cited by other.
"U.S. Appl. No. 09/579,951, Final Office Action mailed Dec. 14, 2001", 8 pgs. cited by other.
"U.S. Appl. No. 09/579,951, Non Final Office Action mailed Jul. 6, 2001", 9 pgs. cited by other.
"U.S. Appl. No. 09/579,951, Notice of Allowance mailed Jul. 10, 2002", 5 pgs. cited by other.
"U.S. Appl. No. 09/579,951, Response filed May 10, 2002 to Final Office Action mailed Dec. 14, 2001", 5 pgs. cited by other.
"U.S. Appl. No. 09/579,951, Response filed Oct. 5, 2001 to Non Final Office Action mailed Jul. 6, 2001", 16 pgs. cited by other.
"U.S. Appl. No. 09/615,588, Notice of Allowance mailed Oct. 4, 2001", 4 pgs. cited by other.
"U.S. Appl. No. 09/661,875, 312 Amendment filed Nov. 21, 2002", 1 pg. cited by other.
"U.S. Appl. No. 09/661,875, Non Final Office Action mailed Mar. 28, 2002", 7 pgs. cited by other.
"U.S. Appl. No. 09/661,875, Notice of Allowance mailed Aug. 23, 2002", 9 pgs. cited by other.
"U.S. Appl. No. 09/661,875, Response filed Jun. 28, 2002 to Non Final Office Action mailed Mar. 28, 2002", 6 pgs. cited by other.
"U.S. Appl. No. 09/693,402, Non final Office Action mailed Apr. 25, 2001", 3 pgs. cited by other.
"U.S. Appl. No. 09/693,402, Notice of Allowance mailed Aug. 28, 2001", 5 pgs. cited by other.
"U.S. Appl. No. 09/693,402, Response filed Jul. 25, 2001 to Non final office action mailed Apr. 25, 2001", 4 pgs. cited by other.
"U.S. Appl. No. 09/748,358, Notice of Allowance mailed Jun. 26, 2002", 6 pgs. cited by other.
"U.S. Appl. No. 09/748,724, Non Final Office Action mailed Dec. 31, 2002", 6 pgs. cited by other.
"U.S. Appl. No. 09/748,724, Notice of Allowance mailed Jun. 15, 2005", 4 pgs. cited by other.
"U.S. Appl. No. 09/748,724, Notice of Allowance mailed Jun. 17, 2003", 5 pgs. cited by other.
"U.S. Appl. No. 09/748,724, Notice of Allowance mailed Dec. 1, 2003", 5 pgs. cited by other.
"U.S. Appl. No. 09/748,724, Response filed Mar. 31, 2003 to Non Final Office Action mailed Dec. 31, 2002", 6 pgs. cited by other.
"U.S. Appl. No. 09/748,796, Amendment filed Nov. 13, 2003", 6 pgs. cited by other.
"U.S. Appl. No. 09/748,796, Non Final Office Action mailed Mar. 18, 2002", 3 pgs. cited by other.
"U.S. Appl. No. 09/748,796, Non Final Office Action mailed Apr. 21, 2003", 5 pgs. cited by other.
"U.S. Appl. No. 09/748,796, Notice of Allowance mailed Feb. 19, 2004", 6 pgs. cited by other.
"U.S. Appl. No. 09/748,796, Notice of Allowance mailed Apr. 25, 2005", 6 pgs. cited by other.
"U.S. Appl. No. 09/748,796, Notice of Allowance mailed Jun. 14, 2006", 8 pgs. cited by other.
"U.S. Appl. No. 09/748,796, Notice of Allowance mailed Aug. 13, 2003", 5 pgs. cited by other.
"U.S. Appl. No. 09/748,796, Notice of Allowance mailed Sep. 30, 2002", 10 pgs. cited by other.
"U.S. Appl. No. 09/748,796, Response filed Jun. 18, 2002 to Non Final Office Action mailed Mar. 18, 2002", 2 pgs. cited by other.
"U.S. Appl. No. 09/748,796, Response filed Jul. 31, 2003 to Non Final Office Action mailed Apr. 21, 2003", 8 pgs. cited by other.
"U.S. Appl. No. 09/751,431, Final Office Action mailed Jan. 13, 2003", 9 pgs. cited by other.
"U.S. Appl. No. 09/751,431, Non Final Office Action mailed Jul. 3, 2002", 9 pgs. cited by other.
"U.S. Appl. No. 09/751,431. Response filed Apr. 14, 2003 to Final Office Action mailed Jan. 13, 2003", 8 pgs. cited by other.
"U.S. Appl. No. 09/751,431. Response filed Nov. 4, 2002 to Non Final Office Action mailed Jul. 3, 2002", 11 pgs. cited by other.
"U.S. Appl. No. 09/792,651, Non-Final Office Action mailed Nov. 20, 2002", 10 pgs. cited by other.
"U.S. Appl. No. 09/837,019, Non Final Office Action mailed Aug. 1, 2001", 4 pgs. cited by other.
"U.S. Appl. No. 09/837,019, Notice of Allowance mailed Feb. 8, 2002", 3 pgs. cited by other.
"U.S. Appl. No. 10/017,800, Advisory Action mailed Apr. 21, 2005", 3 pgs. cited by other.
"U.S. Appl. No. 10/017,800, Advisory Action mailed Apr. 27, 2006", 4 pgs. cited by other.
"U.S. Appl. No. 10/017,800, Appeal Brief filed Jul. 10, 2006", 23 pgs. cited by other.
"U.S. Appl. No. 10/017,800, Final Office Action mailed Feb. 8, 2005", 8 pgs. cited by other.
"U.S. Appl. No. 10/017,800, Final Office Action mailed Feb. 24, 2006", 8 pgs. cited by other.
"U.S. Appl. No. 10/017,800, Final Office Action mailed Nov. 15, 2005", 8 pgs. cited by other.
"U.S. Appl. No. 10/017,800, Non-Final Office Action mailed Jul. 5, 2005", 10 pgs. cited by other.
"U.S. Appl. No. 10/017,800, Non-Final Office Action mailed Aug. 24, 2004", 6 pgs. cited by other.
"U.S. Appl. No. 10/017,800, Notice of Allowance mailed Feb. 20, 2007", 6 pgs. cited by other.
"U.S. Appl. No. 10/017,800, Notice of Allowance mailed Oct. 27, 2006", 6 pgs. cited by other.
"U.S. Appl. No. 10/017,800, Preliminary Amendment filed Jan. 12, 2007", 4 pgs. cited by other.
"U.S. Appl. No. 10/017,800, Response filed Jan. 13, 2006 to Final Ofice Ation mailed Nov. 15, 2005", 14 pgs. cited by other.
"U.S. Appl. No. 10/017,800, Response filed Apr. 5, 2005 to Final Office Action mailed Feb. 8, 2005", 14 pgs. cited by other.
"U.S. Appl. No. 10/017,800, Response filed Apr. 24, 2006 to Final Office Action mailed Feb. 24, 2006", 13 pgs. cited by other.
"U.S. Appl. No. 10/017,800, Response filed Sep. 6, 2005 to Non Final Office Action mailed Jul. 5, 2005", 14 pgs. cited by other.
"U.S. Appl. No. 10/017,800, Response filed Nov. 23, 2004 to Non-Final Office Action mailed Aug. 24, 2004", 15 pgs. cited by other.
"U.S. Appl. No. 10/054,427, Non Final Office Action mailed Jun. 19, 2003", 4 pgs. cited by other.
"U.S. Appl. No. 10/054,427, Notice of Allowance mailed Feb. 26, 2004", 4 pgs. cited by other.
"U.S. Appl. No. 10/054,427, Notice of Allowance mailed Sep. 29, 2003", 5 pgs. cited by other.
"U.S. Appl. No. 10/054,427, Response filed Aug. 21, 2003 to Non Final Office Action mailed Jun. 19, 2003", 6 pgs. cited by other.
"U.S. Appl. No. 10/107,800, Response filed May 9, 2005 to Advisory Action mailed Apr. 21, 2005", 14 pgs. cited by other.
"U.S. Appl. No. 10/211,414, Final Office Action mailed Oct. 29, 2003", 7 pgs. cited by other.
"U.S. Appl. No. 10/211,414, Non Final Office Action mailed Apr. 14, 2003", 8 pgs. cited by other.
"U.S. Appl. No. 10/211,414, Notice of Allowance mailed Feb. 22, 2006", 4 pgs. cited by other.
"U.S. Appl. No. 10/211,414, Notice of Allowance mailed Mar. 15, 2004", 4 pgs. cited by other.
"U.S. Appl. No. 10/211,414, Notice of Allowance mailed May 13, 2005", 4 pgs. cited by other.
"U.S. Appl. No. 10/211,414, Response filed Jul. 14, 2003 to Non Final Office Action mailed Apr. 14, 2003", 14 pgs. cited by other.
"U.S. Appl. No. 10/211,414, Response filed Dec. 29, 2003 to Final Office Action mailed Oct. 29, 2003", 17 pgs. cited by other.
"U.S. Appl. No. 10/274,697, Non-Final Office Action mailed Jul. 9, 2007", 5 pgs. cited by other.
"U.S. Appl. No. 10/274,697, Notice of Allowance mailed Jan. 23, 2008", 4 pgs. cited by other.
"U.S. Appl. No. 10/274,697, Response filed Nov. 8, 2007 to Non-Final Office Action mailed Jul. 9, 2007", 10 pgs. cited by other.
"U.S. Appl. No. 10/304,149, Non-Final Office Action mailed Mar. 3, 2004", 7 pgs. cited by other.
"U.S. Appl. No. 10/304,149, Notice of Allowance mailed Jul. 19, 2005", 7 pgs. cited by other.
"U.S. Appl. No. 10/304,149, Preliminary Amendment filed Mar. 21, 2003", 3 pgs. cited by other.
"U.S. Appl. No. 10/304,149, Response filed Jul. 6, 2004 to Non Final Office Action mailed Mar. 3, 2004", 6 pgs. cited by other.
"U.S. Appl. No. 10/306,514, Non-Final Office Action mailed Mar. 24, 2005", 7 pgs. cited by other.
"U.S. Appl. No. 10/306,514, Notice of Allowance mailed Sep. 15, 2005", 4 pgs. cited by other.
"U.S. Appl. No. 10/306,514, Response filed Jul. 25, 2005 to Non Final Office Action mailed Mar. 24, 2005", 6 pgs. cited by other.
"U.S. Appl. No. 10/334,397, Non Final Office Action mailed May 9, 2003", 7 pgs. cited by other.
"U.S. Appl. No. 10/334,397, Notice of Allowance mailed Sep. 11, 2003", 5 pgs. cited by other.
"U.S. Appl. No. 10/334,397, Response filed Aug. 8, 2003 to Non Final Office Action mailed May 9, 2003", 11 pgs. cited by other.
"U.S. Appl. No. 10/394,497, Non Final Office Action mailed Mar. 9, 2006", 10 pgs. cited by other.
"U.S. Appl. No. 10/394,497, Notice of Allowance mailed Oct. 10, 2006", 4 pgs. cited by other.
"U.S. Appl. No. 10/394,497, Response filed Jul. 10, 2006 to Non Final Office Action mailed Mar. 9, 2006", 14 pgs. cited by other.
"U.S. Appl. No. 10/713,556, Non Final Office Action mailed Jun. 12, 2006", 8 pgs. cited by other.
"U.S. Appl. No. 10/713,556, Notice of Allowance mailed Dec. 18, 2006", 9 pgs. cited by other.
"U.S. Appl. No. 10/713,556, Response filed Oct. 12, 2006 to Non Final Office Action mailed Jun. 12, 2006", 9 pgs. cited by other.
"U.S. Appl. No. 10/746,856, Notice of Allowance mailed Oct. 25, 2007", 6 pgs. cited by other.
"U.S. Appl. No. 10/746,856, Response filed Aug. 6, 2007 to Final Office Action mailed Jun. 5, 2007", 9 pages. cited by other.
"U.S. Appl. No. 10/746,856, Supplemental Notice of Allowability mailed Nov. 14, 2007", 4 pgs. cited by other.
"U.S. Appl. No. 10/792,663, Notice of Allowance mailed Dec. 13, 2005", 5 pgs. cited by other.
"U.S. Appl. No. 10/792,663, Preliminary Amendment filed Jul. 26, 2004", 5 pgs. cited by other.
"U.S. Appl. No. 10/889,354, Non Final Office Action mailed Jun. 5, 2007", 4 pgs. cited by other.
"U.S. Appl. No. 10/889,354, Notice of Allowance mailed Jan. 23, 2008", 4 pgs. cited by other.
"U.S. Appl. No. 10/889,354, Notice of Allowance mailed Sep. 28, 2007", 4 pgs. cited by other.
"U.S. Appl. No. 10/889,354, Response filed Sep. 5, 2007 to Non-Final Office Action mailed Jun. 5, 2007", 7 pgs. cited by other.
"U.S. Appl. No. 11/380,148, Examiner Interview Summary mailed Apr. 3, 2009", 1 pg. cited by other.
"U.S. Appl. No. 11/380,148, Final Office Action mailed Nov. 10, 2009", 5 pgs. cited by other.
"U.S. Appl. No. 11/380,148, Non Final Office Action mailed Apr. 3, 2009", 8 pgs. cited by other.
"U.S. Appl. No. 11/380,148, Notice of Allowance mailed Feb. 22, 2010", 5 pgs. cited by other.
"U.S. Appl. No. 11/380,148, Response filed Jan. 11, 2010 to Final Office Action mailed Nov. 10, 2009", 5 pgs. cited by other.
"U.S. Appl. No. 11/380,148, Response filed Jul. 6, 2009 to Non Final Office Action mailed Apr. 3, 2009", 8 pgs. cited by other.
"U.S. Appl. No. 11/380,148, Response filed Dec. 1, 2008 to Restriction Requirement mailed Oct. 29, 2008", 6 pgs. cited by other.
"U.S. Appl. No. 11/380,148, Restriction Requirement mailed Mar. 6, 2009", 8 pgs. cited by other.
"U.S. Appl. No. 11/380,148, Restriction Requirement mailed Oct. 29, 2008", 7 pgs. cited by other.
"U.S. Appl. No. 11/423,516, Examiner Interview Summary mailed Jan. 19, 2011", 3 pgs. cited by other.
"U.S. Appl. No. 11/423,516, Final Office Action mailed Jul. 6, 2010", 10 pgs. cited by other.
"U.S. Appl. No. 11/423,516, Non Final Office Action mailed Oct. 2, 2009", 9 pgs. cited by other.
"U.S. Appl. No. 11/423,516, Non Office Action mailed Jan. 26, 2011", 7 pgs. cited by other.
"U.S. Appl. No. 11/423,516, Preliminary Amendment filed Oct. 5, 2006", 7 pgs. cited by other.
"U.S. Appl. No. 11/423,516, Response filed Jan. 6, 2011 to Final Office Action mailed Jul. 6, 2010", 12 pgs. cited by other.
"U.S. Appl. No. 11/423,516, Response filed Mar. 31, 2010 to Non Final Office Action mailed Oct. 2, 2009", 11 pgs. cited by other.
"U.S. Appl. No. 11/423,516, Response filed Apr. 26, 2011 to Non Final Office Action mailed Jan. 26, 2011", 8 pgs. cited by other.
"U.S. Appl. No. 11/549,368, Notice of Allowance mailed Feb. 1, 2010", 6 pgs. cited by other.
"U.S. Appl. No. 11/549,368, Notice of Allowance mailed May 17, 2010", 4 pgs. cited by other.
"U.S. Appl. No. 11/673,098 Final Office Action mailed Oct. 4, 2010", 8 pgs. cited by other.
"U.S. Appl. No. 11/673,098, Final Office Action mailed Aug. 31, 2009", 6 pgs. cited by other.
"U.S. Appl. No. 11/673,098, Non-Final Office Action mailed Feb. 4, 2009", 6 pgs. cited by other.
"U.S. Appl. No. 11/673,098, Non-Final Office Action mailed Mar. 24, 2010", 7 pgs. cited by other.
"U.S. Appl. No. 11/673,098, Response filed Feb. 3, 2011 to Final Office Action mailed Oct. 4, 2010", 9 pgs. cited by other.
"U.S. Appl. No. 11/673,098, Response filed May 4, 2009 to Non Final Office Action mailed Feb. 4, 2009", 7 pgs. cited by other.
"U.S. Appl. No. 11/673,098, Response filed Jun. 24, 2010 to Non Final Office Action mailed Mar. 24, 2010", 8 pgs. cited by other.
"U.S. Appl. No. 11/673,098, Response under 37 C.F.R. 1.116, filed Dec. 15, 2009", 7 pgs. cited by other.
"U.S. Appl. No. 11/676,464, Preliminary Amendment filed Feb. 19, 2007", 11 pgs. cited by other.
"U.S. Appl. No. 11/733,332, Final Office Action mailed Aug. 3, 2009", 9 pgs. cited by other.
"U.S. Appl. No. 11/733,332, Non-Final Office Action mailed Feb. 17, 2009", 7 pgs. cited by other.
"U.S. Appl. No. 11/733,332, Notice of Allowance mailed Jul. 14, 2010", 7 pgs. cited by other.
"U.S. Appl. No. 11/733,332, Response filed Oct. 5, 2009 to Final Office Action mailed Aug. 3, 2009", 11 pgs. cited by other.
"U.S. Appl. No. 11/759,394, Final Office Action mailed Apr. 28, 2011", 7 pgs. cited by other.
"U.S. Appl. No. 11/759,394, Non Final Office Action mailed Dec. 10, 2010", 10 pgs. cited by other.
"U.S. Appl. No. 11/759,394, Response filed Mar. 10, 2011 to Non Final Office Action mailed Dec. 10, 2010", 12 pgs. cited by other.
"U.S. Appl. No. 12/706,982, Non Final Office Action mailed May 13, 2011", 5 pgs. cited by other.
"U.S. Appl. No. 12/891,669, Non Final Office Action mailed Dec. 15, 2010", 5 pgs. cited by other.
"U.S. Appl. No. 12/891,669, Notice of Allowance mailed Apr. 5, 2011", 6 pgs. cited by other.
"U.S. Appl. No. 12/891,669, Response filed Mar. 15, 2011 to Non Final Office Action mailed Dec. 15, 2010", 7 pgs. cited by other.
"European Application Serial No. 00936114.6, Communication mailed Sep. 15, 2004", 2 pgs. cited by other.
"European Application Serial No. 00936114.6, Communication mailed Oct. 19, 2006", 2 pgs. cited by other.
"European Application Serial No. 00936114.6, Response filed Mar. 24, 2005 to Communication mailed Sep. 15, 2004", 23 pgs. cited by other.
"European Application Serial No. 00936114.6, Response filed Apr. 30, 2007 to Communication mailed Oct. 19, 2006", 16 pgs. cited by other.
"European Application Serial No. 00936114.8, Response to Summons to Attend Oral Proceedings Filed Nov. 15, 2010", 10 pgs. cited by other.
"European Application Serial No. 00936114.8, Rule 71(3) re: Approval of Text/Translation/Grant & Print Fees mailed Jan. 5, 2011", 67. cited by other.
"European Application Serial No. 00936114.8, Summons to Attend Oral Proceedings mailed Jun. 23, 2010", 2 pgs. cited by other.
"European Application Serial No. 01999174.4, Communication mailed Apr. 12, 2005", 4 pgs. cited by other.
"European Application Serial No. 01999174.4, Communication maileed Apr. 21, 2009", 3 pgs. cited by other.
"European Application Serial No. 01999174.4, Response filed Aug. 19, 2009 to Communication mailed on Apr. 21, 2009", 6 pgs. cited by other.
"European Application Serial No. 01999174.4, Response filed Oct. 12, 2005 to Communication mailed Apr. 12, 2005", 10 pgs. cited by other.
"European Application Serial No. 10153647.2, European Search Report mailed Apr. 26, 2010", 5 pgs. cited by other.
"European Application Serial No. 10153647.2, Office Action mailed Jun. 14, 2010", 5 pgs. cited by other.
"International Application Serial No. PCT/US00/13835, International Preliminary Examination Report completed Aug. 20, 2001", 5 pgs. cited by other.
"International Application Serial No. PCT/US00/13835, International Search Report mailed Oct. 2, 2000", 6 pgs. cited by other.
"International Application Serial No. PCT/US00/13835, Written Opinion mailed Mar. 8, 2001", 5 pgs. cited by other.
"International Application Serial No. PCT/US00/13838, Amendment filed May 9, 2001 in Response to Written Opinion mailed Feb. 14, 2001", 13 pgs. cited by other.
"International Application Serial No. PCT/US00/13838, International Preliminary Examination Report completed Jul. 18, 2001", 15 pgs. cited by other.
"International Application Serial No. PCT/US00/13838, Written Opinion mailed Feb. 14, 2001", 8 pgs. cited by other.
"International Application Serial No. PCT/US00/13863, Amendment filed Jun. 12, 2001 in Response to Written Opinion mailed Mar. 14, 2001", 12 pgs. cited by other.
"International Application Serial No. PCT/US00/13863, International Preliminary Examination Report completed Aug. 24, 2001", 12 pgs. cited by other.
"International Application Serial No. PCT/US00/13863, International Search Report mailed Oct. 2, 2000", 3 pgs. cited by other.
"International Application Serial No. PCT/US00/13863, Written Opinion mailed Mar. 14, 2001", 7 pgs. cited by other.
"International Application Serial No. PCT/US00/13877, Amendments filed Jul. 26, 2001 in Response to Written Opinion", 11 pgs. cited by other.
"International Application Serial No. PCT/US00/13877, International Preliminary Examination Report completed Aug. 30, 2001", 15 pgs. cited by other.
"International Application Serial No. PCT/US00/13877, International Search Report mailed Oct. 2, 2000", 4 pgs. cited by other.
"International Application Serial No. PCT/US00/13877, Written Opinion mailed May 28, 2001", 9 pgs. cited by other.
"International Application Serial No. PCT/US01/49660, International Preliminary Examination Report completed Dec. 19, 2002", 2 pgs. cited by other.
"International Application Serial No. PCT/US01/49660, International Search Report mailed Oct. 1, 2002", 8 pgs. cited by other.
"International Application Serial No. PCT/US01/49660, Written Opinion mailed Oct. 1, 2002", 2 pgs. cited by other.
"Japanese Application Serial No. 2000-619502, Notice of Reasons for Rejection mailed Mar. 25, 2008", (w/ English Translation), 5 pgs. cited by other.
"Japanese Application Serial No. 2000-619502, Response and Amendment Claims filed Jun. 11, 2008 to Notice of Reasons for Rejection mailed Mar. 25, 2008", (w/ English Translation of Amended Claims), 14 pgs. cited by other.
"Pacemaker System Guide", .COPYRGT. 2001 Guidant Corporation, 240 pgs. cited by other.
"Prosecution File History for U.S. Appl. No. 10/462,029, filed Jun. 13, 2003", (issued as US 7,142,915), 15 pgs. cited by other.
Alonso, C., "Electrocardiographic Predictive Factors of Long-Term Clinical Improvement with Multisite Biventricular Pacing in Advanced Heart Failure", The American Journal of Cardiology (US), vol. 84, No. 12, (Dec. 1999), 1417-1421. cited by other.
Das, G., "QT interval and repolarization time in patients with intraventricular conduction delay", J Electrocardiol., 23(1), (Jan. 1990), 49-52. cited by other.
Guidant, "CONTAK CD.RTM. CRT-D 1823", Physician's System Manual, Cardiac Resynchronization Therapy Defibrillator, (2002), 1-176. cited by other.
Guidant, "CONTAK.RTM. Renewal.TM. Model H135", System Guide, (2003), 1-331. cited by other.
Hsia, P. W., et al., "Improved Nonthoractomy Defibrillation Based on Ventricular Fibrillation Waveform Characteristics", PACE, 18-NASPE Abstracts, Abstract No. 29, (Apr. 1995), 803. cited by other.
Hsu, W., et al., "Effect of Shock Timing on Defibrillation Success", Pacing Clin Electrophysiol., 20(1 Pt 2), (Jan. 1997), 153-157. cited by other.
Medtronic, "INSYNC.RTM. Device Model 8040", Device Reference Guide, (Aug. 2001), 1-276. cited by other.
Medtronic, "INSYNC.RTM. ICD 7272", System Reference Guide, Dual chamber implantable cardioverter defibrillator with cardiac resynchronization therapy. A guide to the operation and programming of the 7272 InSync ICD Dual Chamber ImplantableCardioverter Defibrillator, (Jun. 2002), 1-367. cited by other.
Medtronic, "INSYNC.RTM. Marquis.TM. 7277", Reference Manual, Dual Chamber Implantable Cardioverter Defibrillator, (Mar. 2003), 1-435. cited by other.
Medtronic, "INSYNC.RTM. Model 8040 Device Programming Guide", Device Programming Guide, Device Model 8040 & Programmer Software Model 9980, (2001), 1-204. cited by other.
Prinzen, F. W., et al., "Optimization of ventricular function by improving the activation sequence during ventricular pacing", Pacing Clin Electrophysiol., 21(11 Pt 2), (Nov. 1998), 2256-60. cited by other.
Saxon, L. A., et al., "Acute effects of intraoperative multisite ventricular pacing on left ventricular function and activation/contraction sequence in patients with depressed ventricular function.", J Cardiovasc Electrophysiol., 9(1), (Jan. 1998),13-21. cited by other.
Abstract: A cardiac rhythm management system includes techniques for computing an indicated pacing interval, AV delay, or other timing interval. In one embodiment, a variable indicated pacing interval is computed based at least in part on an underlying intrinsic heart rate. The indicated pacing interval is used to time the delivery of biventricular coordination therapy even when ventricular heart rates are irregular, such as in the presence of atrial fibrillation. In another embodiment, a variable filter indicated AV interval is computed based at least in part on an underlying intrinsic AV interval. The indicated AV interval is used to time the delivery of atrial tracking biventricular coordination therapy when atrial heart rhythms are not arrhythmic. Other indicated timing intervals may be similarly determined. The indicated pacing interval, AV delay, or other timing interval can also be used in combination with a sensor indicated rate indicator.
1. A method for operating a cardiac pacemaker, comprising: sensing a ventricle; pacing a ventricle upon expiration of an atrio-ventricular escape interval initiated by anatrial event and stopped by a ventricular sense; measuring an intrinsic atrio-ventricular interval as the time between the atrial event and the ventricular sense during a cardiac cycle when no ventricular pace is delivered; after the cardiac cycle whenno ventricular pace is delivered, decreasing the atrio-ventricular escape interval in a manner dependent upon the measured intrinsic atrio-ventricular interval as a mathematical function thereof, wherein the atrio-ventricular escape interval is decreasedby computing a weighted average of the atrio-ventricular escape interval and the measured intrinsic atrio-ventricular interval multiplied by a scaling factor; and, after a cardiac cycle when a ventricular pace is delivered, increasing theatrio-ventricular escape interval.
6. A cardiac pacing device, comprising: sensing circuits for sensing depolarizations in a ventricle and an atrium; a pacing circuit for delivering pacing pulses to the ventricle; a controller for controlling the delivery of paces such thatthe ventricle is paced upon expiration of an atrio-ventricular escape interval initiated by an atrial event and stopped by a ventricular sense; wherein the controller is further programmed to: measure an intrinsic atrio-ventricular interval as the timebetween the atrial event and the ventricular sense during a cardiac cycle when no ventricular pace is delivered; after the cardiac cycle when no ventricular pace is delivered, decrease the atrio-ventricular escape interval in a manner dependent upon themeasured intrinsic atrio-ventricular interval as a mathematical function thereof, wherein the atrio-ventricular escape interval is decreased by computing a weighted average of the atrio-ventricular escape interval and the measured intrinsicatrio-ventricular interval multiplied by a scaling factor; and, after a cardiac cycle when a ventricular pace is delivered, increase the atrio-ventricular escape interval.
10. The device of claim 6, wherein the controller is further programmed such that the atrio-ventricular escape interval is increased after each ventricular pace by multiplying the atrio-ventricular escape interval by a specified filtercoefficient.
When functioning properly, the human heart maintains its own intrinsic rhythm, and is capable of pumping adequate blood throughout the body's circulatory system. However, some people have irregular cardiac rhythms, referred to as cardiacarrhythmias. Such arrhythmias result in diminished blood circulation. One mode of treating cardiac arrhythmias uses drug therapy. Drugs are often effective at restoring normal heart rhythms. However, drug therapy is not always effective for treatingarrhythmias of certain patients. For such patients, an alternative mode of treatment is needed. One such alternative mode of treatment includes the use of a cardiac rhythm management system. Such systems are often implanted in the patient and delivertherapy to the heart.
Cardiac rhythm management systems also include cardioverters or defibrillators that are capable of delivering higher energy electrical stimuli to the heart. Defibrillators are often used to treat patients with tachyarrhythmias, that is, heartsthat beat too quickly. Such too-fast heart rhythms also cause diminished blood circulation because the heart isn't allowed sufficient time to fill with blood before contracting to expel the blood. Such pumping by the heart is inefficient. Adefibrillator is capable of delivering an high energy electrical stimulus that is sometimes referred to as a defibrillation countershock. The countershock interrupts the tachyarrhythmia, allowing the heart to reestablish a normal rhythm for theefficient pumping of blood. In addition to pacers, cardiac rhythm management systems also include, among other things, pacer/defibrillators that combine the functions of pacers and defibrillators, drug delivery devices, and any other implantable orexternal systems or devices for diagnosing or treating cardiac arrhythmias.
One problem faced by cardiac rhythm management systems is the treatment of congestive heart failure (also referred to as "CHF"). Congestive heart failure, which can result from long-term hypertension, is a condition in which the muscle in thewalls of at least one of the right and left sides of the heart deteriorates. By way of example, suppose the muscle in the walls of left side of the heart deteriorates. As a result, the left atrium and left ventricle become enlarged, and the heartmuscle displays less contractility. This decreases cardiac output of blood through the circulatory system which, in turn, may result in an increased heart rate and less resting time between heartbeats. The heart consumes more energy and oxygen, and itscondition typically worsens over a period of time.
In the above example, as the left side of the heart becomes enlarged, the intrinsic electrical heart signals that control heart rhythm are also affected. Normally, such intrinsic signals originate in the sinoatrial (SA) node in the upper rightatrium, traveling through and depolarizing the atrial heart tissue such that resulting contractions of the right and left atria are triggered. The intrinsic atrial heart signals are received by the atrioventricular (AV) node which, in turn, triggers asubsequent ventricular intrinsic heart signal that travels through and depolarizes the ventricular heart tissue such that resulting contractions of the right and left ventricles are triggered substantially simultaneously.
In the above example, where the left side of the heart has become enlarged due to congestive heart failure, however, the ventricular intrinsic heart signals may travel through and depolarize the left side of the heart more slowly than in theright side of the heart. As a result, the left and right ventricles do not contract simultaneously, but rather, the left ventricle contracts after the right ventricle. This reduces the pumping efficiency of the heart. Moreover, in the case of leftbundle branch block (LBBB), for example, different regions within the left ventricle may not contract together in a coordinated fashion.
Congestive heart failure can be treated by biventricular coordination therapy that provides pacing pulses to both right and left ventricles. See, e.g., Mower U.S. Pat. No. 4,928,688. Congestive heart failure may also result in an overly longatrioventricular (AV) delay between atrial and ventricular contractions, again reducing the pumping efficiency of the heart. There is a need to provide congestive heart failure patients with improved pacing and coordination therapies for improving theAV delay, coordinating ventricular contractions, or otherwise increasing heart pumping efficiency.
Another problem faced by cardiac rhythm management systems is the presence of atrial tachyarrhythmias, such as atrial fibrillation, occurring in patients having congestive heart failure. Atrial fibrillation is a common cardiac arrhythmia thatreduces the pumping efficiency of the heart, though not to as great a degree as in ventricular fibrillation. However, this reduced pumping efficiency requires the ventricle to work harder, which is particularly undesirable in congestive heart failure orother sick patients that cannot tolerate additional stresses. Even though a congestive heart failure may have adequate ventricular coordination and cardiac output in the presence of a normal sinus rhythm, when atrial tachyarrhythmia is present,ventricular incoordination may occur, seriously worsening cardiac function.
Moreover, some devices treating congestive heart failure sense atrial heart rate and provide biventricular coordination therapy at a ventricular heart rate that tracks the atrial heart rate. See, e.g., Mower U.S. Pat. No. 4,928,688. Suchatrial-tracking devices require a normal sinus rhythm to ensure proper delivery of biventricular coordination therapy. In the presence of atrial tachyarrhythmias, such as atrial fibrillation, however, such atrial tracking biventricular coordinationtherapy could lead to too-fast and irregular biventricular coordination that is ineffective and even dangerous.
Another problem is that atrial fibrillation may induce irregular ventricular heart rhythms by processes that are yet to be fully understood. Such induced ventricular arrhythmias compromise pumping efficiency even more drastically than atrialarrhythmias. Some devices treating congestive heart failure provide biventricular coordination therapy that does not track the atrial heart rate, but instead, a sensed ventricular contraction in a first ventricle triggers a ventricular pace in the otherventricle, or in both ventricles. See, e.g., Mower U.S. Pat. No. 4,928,688. Even if such biventricular coordination therapy is ventricular-triggered rather than atrial-tracking, the presence of atrial tachyarrhythmias could lead to ventriculararrhythmias, such that the biventricular coordination therapy becomes ineffective and even dangerous because it is too-fast or irregular because of the irregular ventricular heart rate. For these and other reasons, there is a need to provide congestiveheart failure patients with improved pacing and coordination therapies for improving the AV delay, coordinating ventricular contractions, or otherwise increasing heart pumping efficiency, even during atrial arrhythmias such as atrial fibrillation.
The present system provides, among other things, a cardiac rhythm management system including techniques for computing an indicated pacing interval, AV delay, or other timing interval. In one embodiment, a variable indicated pacing interval iscomputed based at least in part on an underlying intrinsic heart rate. The indicated pacing interval is used to time the delivery of biventricular coordination therapy even when ventricular heart rates are irregular, such as in the presence of atrialfibrillation. In another embodiment, a variable filter indicated AV interval is computed based at least in part on an underlying intrinsic AV interval. The indicated AV interval is used to time the delivery of atrial tracking biventricular coordinationtherapy when atrial heart rhythms are not arrhythmic. Other indicated timing intervals may be similarly determined. The indicated pacing interval, AV delay, or other timing interval can also be used in combination with a sensor indicated rateindicator.
In one embodiment, the system includes a first method. Actual timing intervals between cardiac events are obtained. The system computes a first indicated timing interval based at least on a most recent actual timing interval duration and aprevious value of the first indicated timing interval. The system provides pacing therapy based on the first indicated timing interval.
In another embodiment, the system includes a second method. The system obtains atrio-ventricular (AV) intervals between atrial events and successive ventricular events. The system computes a first indicated AV interval based at least on a mostrecent AV interval duration and a previous value of the first indicated AV interval. The system provides pacing therapy based on the first indicated AV interval.
In another embodiment, the system includes a third method. The system obtains V-V intervals between ventricular beats. The system computes a first indicated pacing interval based at least on a most recent V-V interval duration and a previousvalue of the first indicated pacing interval. The system provides pacing therapy to first and second ventricles, based on the first indicated pacing interval.
Another embodiment provides a cardiac rhythm management system that includes a sensing circuit for sensing events, a controller obtaining timing intervals between events and computing a first indicated timing interval based at least on a mostrecent actual timing interval duration and a previous value of the first indicated timing interval, and a therapy circuit, providing pacing therapy based on the first indicated timing interval.
Another embodiment provides a cardiac rhythm management system that includes at least one ventricular sensing circuit, a controller, and a ventricular therapy circuit. The controller includes a V-V interval timer obtaining V-V intervals betweensuccessive events in at least one ventricle, a first register for storing a first indicated pacing interval, and a filter updating the first indicated pacing interval based on a most recent V-V interval provided by the VV interval timer and previousvalue of the first indicated pacing interval stored the first register. The ventricular therapy circuit provides pacing therapy to first and second ventricles based at least partially on the first indicated pacing interval. Other aspects of theinvention will be apparent on reading the following detailed description of the invention and viewing the drawings that form a part thereof.
FIG. 12 is a graph illustrating generally another embodiment of operating a filter to provide the first indicated pacing rate, such as a VRR indicated rate, and delivering therapy based on the first indicated pacing rate and based on a secondindicated pacing rate, such as a sensor indicated rate.
In the following detailed description, reference is made to the accompanying drawings which form a part hereof, and in which is shown by way of illustration specific embodiments in which the invention may be practiced. These embodiments aredescribed in sufficient detail to enable those skilled in the art to practice the invention, and it is to be understood that the embodiments may be combined, or that other embodiments may be utilized and that structural, logical and electrical changesmay be made without departing from the spirit and scope of the present invention. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the present invention is defined by the appended claims and theirequivalents. In the drawings, like numerals describe substantially similar components throughout the several views. Like numerals having different letter suffixes represent different instances of substantially similar components.
As stated earlier, one potential cause of irregularity of ventricular contractions arises during atrial tachyarrhythmias, such as atrial fibrillation. During atrial fibrillation, irregular ventricular contractions may be caused by an atrialtachyarrhythmia that is conducted to the ventricles. Pacing the ventricles regularizes the ventricular heart rate by establishing retrograde conduction from the ventricles. This, in turn, is believed to block forward conduction of atrial signalsthrough the atrioventricular (A-V) node. As a result, irregular atrial signals do not trigger resulting irregular ventricular contractions.
One therapy for treating irregular ventricular contractions during atrial fibrillation is to increase the ventricular heart rate by pacing the ventricles at a higher rate than the average unpaced (intrinsic) ventricular heart rate. Such therapyimproves cardiac output because it stabilizes the rate of ventricular contractions to avoid short periods between contractions and/or long periods without a contraction. Such therapy is also believed to decrease the ability of the atrial fibrillation toinduce irregular ventricular contractions. Additionally, pacing the ventricles at above the average intrinsic ventricular heart rate can provide coordination therapy. Coordination therapy applies the pacing stimulation to one ventricle at multiplesites, to both ventricles at a single site in each ventricle, or to both ventricles at multiple sites in each ventricle. Coordination therapy is applied to the sites in a fashion that coordinates the sequence of contraction in ventricular heart tissue. Coordination therapy is believed to increase systolic pulse pressure in patients with ventricular conduction disorders, such as left bundle branch block (LBBB), associated with uncoordinated ventricular contractions. Coordination therapy also decreasesthe time required for systolic contraction, leaving more time for diastolic ventricular filling, thereby also improving the end diastolic pressure.
This document describes, among other things, a cardiac rhythm management system providing a method and apparatus for treating irregular ventricular contractions during atrial arrhythmia by actively stabilizing the ventricular heart rate toobtain less potentially proarrhythmic conditions for delivering the atrial tachyarrhythmia therapy. One suitable technique for stabilizing ventricular heart rate is referred to as Ventricular Rate Regularization, described in Krig et al. U.S. patentapplication Ser. No. 09/316,515 entitled "Method and Apparatus for Treating Irregular Ventricular Contractions Such As During Atrial Arrhythmia," filed May 21, 1999, now issued as U.S. Pat. No. 7,062,325, assigned to the assignee of the present patentapplication, and which is herein incorporated by reference in its entirety.
FIG. 1 is a schematic drawing illustrating, by way of example, but not by way of limitation, one embodiment of portions of a cardiac rhythm management system 100 and an environment in which it is used. In FIG. 1, system 100 includes animplantable cardiac rhythm management device 105, also referred to as an electronics unit, which is coupled by an intravascular endocardial lead 110, or other lead, to a heart 115 of patient 120. System 100 also includes an external programmer 125providing wireless communication with device 105 using a telemetry device 130. Catheter lead 110 includes a proximal end 135, which is coupled to device 105, and a distal end 140, which is coupled to one or more portions of heart 115.
FIG. 2 is a schematic drawing illustrating, by way of example, but not by way of limitation, one embodiment of device 105 coupled by leads 110A-B to heart 115, which includes a right atrium 200A, a left atrium 200B, a right ventricle 205A, aleft ventricle 205B, and a coronary sinus 220 extending from right atrium 200A. In this embodiment, atrial lead 110A includes electrodes (electrical contacts) disposed in, around, or near an atrium 200 of heart 115, such as ring electrode 225 and tipelectrode 230, for sensing signals and/or delivering pacing therapy to the atrium 200. Lead 110A optionally also includes additional electrodes, such as for delivering atrial and/or ventricular cardioversion/defibrillation and/or pacing therapy to heart115.
In FIG. 2, a ventricular lead 110B includes one or more electrodes, such as tip electrode 235 and ring electrode 240, for delivering sensing signals and/or delivering pacing therapy. Lead 110B optionally also includes additional electrodes,such as for delivering atrial and/or ventricular cardioversion/defibrillation and/or pacing therapy to heart 115. Device 105 includes components that are enclosed in a hermetically-sealed can 250. Additional electrodes may be located on the can 250, oron an insulating header 255, or on other portions of device 105, for providing unipolar pacing and/or defibrillation energy in conjunction with the electrodes disposed on or around heart 115. Other forms of electrodes include meshes and patches whichmay be applied to portions of heart 115 or which may be implanted in other areas of the body to help "steer" electrical currents produced by device 105. The present method and apparatus will work in a variety of configurations and with a variety ofelectrical contacts or "electrodes."
FIG. 3 is a schematic diagram illustrating generally, by way of example, but not by way of limitation, one embodiment of portions of device 105, which is coupled to heart 115. Device 105 includes a power source 300, an atrial sensing circuit305, a ventricular sensing circuit 310, a ventricular therapy circuit 320, and a controller 325.
Atrial sensing circuit 305 is coupled by atrial lead 110A to heart 115 for receiving, sensing, and/or detecting electrical atrial heart signals. Such atrial heart signals include atrial activations (also referred to as atrial depolarizations orP-waves), which correspond to atrial contractions. Such atrial heart signals include normal atrial rhythms, and abnormal atrial rhythms including atrial tachyarrhythmias, such as atrial fibrillation, and other atrial activity. Atrial sensing circuit305 provides one or more signals to controller 325, via node/bus 327, based on the received atrial heart signals. Such signals provided to controller 325 indicate, among other things, the presence of atrial fibrillation.
Ventricular sensing circuit 310 is coupled by ventricular lead 110B to heart 115 for receiving, sensing, and/or detecting electrical ventricular heart signals, such as ventricular activations (also referred to as ventricular depolarizations orR-waves), which correspond to ventricular contractions. Such ventricular heart signals include normal ventricular rhythms, and abnormal ventricular rhythms, including ventricular tachyarrhythmias, such as ventricular fibrillation, and other ventricularactivity, such as irregular ventricular contractions resulting from conducted signals from atrial fibrillation. Ventricular sensing circuit 310 provides one or more signals to controller 325, via node/bus 327, based on the received ventricular heartsignals. Such signals provided to controller 325 indicate, among other things, the presence of ventricular depolarizations, whether regular or irregular in rhythm.
Ventricular therapy circuit 320 provides ventricular pacing therapy, as appropriate, to electrodes located at or near one of the ventricles 205 of heart 115 for obtaining resulting evoked ventricular depolarizations. In one embodiment,ventricular therapy circuit 320 also provides cardioversion/defibrillation therapy, as appropriate, to electrodes located at or near one of the ventricles 205 of heart 115, for terminating ventricular fibrillation and/or other ventriculartachyarrhythmias.
Controller 325 controls the delivery of therapy by ventricular therapy circuit 320 and/or other circuits, based on heart activity signals received from atrial sensing circuit 305 and ventricular sensing circuit 310, as discussed below. Controller 325 includes various modules, which are implemented either in hardware or as one or more sequences of steps carried out on a microprocessor or other controller. Such modules are illustrated separately for conceptual clarity; it is understoodthat the various modules of controller 325 need not be separately embodied, but may be combined and/or otherwise implemented, such as in software/firmware.
In general terms, sensing circuits 305 and 310 sense electrical signals from heart tissue in contact with the catheter leads 110A-B to which these sensing circuits 305 and 310 are coupled. Sensing circuits 305 and 310 and/or controller 325process these sensed signals. Based on these sensed signals, controller 325 issues control signals to therapy circuits, such as ventricular therapy circuit 320, if necessary, for the delivery of electrical energy (e.g., pacing and/or defibrillationpulses) to the appropriate electrodes of leads 110A-B. Controller 325 may include a microprocessor or other controller for execution of software and/or firmware instructions. The software of controller 325 may be modified (e.g., by remote externalprogrammer 105) to provide different parameters, modes, and/or functions for the implantable device 105 or to adapt or improve performance of device 105.
In one further embodiment, one or more sensors, such as sensor 330, may serve as inputs to controller 325 for adjusting the rate at which pacing or other therapy is delivered to heart 115. One such sensor 330 includes an accelerometer thatprovides an input to controller 325 indicating increases and decreases in physical activity, for which controller 325 increases and decreases pacing rate, respectively. Another such sensor includes an impedance measurement, obtained from bodyelectrodes, which provides an indication of increases and decreases in the patient's respiration, for example, for which controller 325 increases and decreases pacing rate, respectively. Any other sensor 330 providing an indicated pacing rate can beused.
FIG. 4 is a schematic diagram illustrating generally, by way of example, but not by way of limitation, one embodiment of controller 325 that includes several different inputs to modify the rate at which pacing or other therapy is delivered. Forexample, Input #1 may provide information about left ventricular rate, Input #2 may provide an accelerometer-based indication of activity, and Input #3 may provide an impedance-based indication of respiration, such as minute ventilation. Based on atleast one of these and/or other inputs, controller 325 provides an output indication of pacing rate as a control signal delivered to a therapy circuit, such as to ventricular therapy circuit 320. Ventricular therapy circuit 320 issues pacing pulsesbased on one or more such control signals received from controller 325. Control of the pacing rate may be performed by controller 325, either alone or in combination with peripheral circuits or modules, using software, hardware, firmware, or anycombination of the like. The software embodiments provide flexibility in how inputs are processed and may also provide the opportunity to remotely upgrade the device software while still implanted in the patient without having to perform surgery toremove and/or replace the device 105.
FIG. 5 is a schematic diagram illustrating generally, by way of example, but not by way of limitation, one conceptualization of portions of controller 325. At least one signal from ventricular sensing circuit 310 is received by ventricularevent module 500, which recognizes the occurrence of ventricular events included within the signal. Such events are also referred to as "beats," "activations," "depolarizations," "QRS complexes," "R-waves," "contractions." Ventricular event module 500detects intrinsic events (also referred to as sensed events) from the signal obtained from ventricular sensing circuit 310. Ventricular event module 500 also detects evoked events (resulting from a pace) either from the signal obtained from ventricularsensing circuit 310, or preferably from a ventricular pacing control signal obtained from pacing control module 505, which also triggers the delivery of a pacing stimulus by ventricular therapy circuit 320. Thus, ventricular events include bothintrinsic/sensed events and evoked/paced events.
A time interval between successive ventricular events, referred to as a V-V interval, is recorded by a first timer, such as V-V interval timer 510. A filter 515 computes a "first indicated pacing interval," i.e., one indication of a desiredtime interval between ventricular events or, stated differently, a desired ventricular heart rate. The first indicated pacing interval is also referred to as a ventricular rate regularization (VRR) indicated pacing interval. In various embodiments,filter 515 includes an averager, a weighted averager, a median filter, an infinite (IIR) filter, a finite impulse response (FIR) filter, or any other analog or digital signal processing circuit providing the desired signal processing described moreparticularly below.
In one embodiment, filter 515 computes a new value of the first indicated pacing interval based on the duration of the most recent V-V interval recorded by timer 510 and on a previous value of the first indicated pacing interval stored in firstindicated pacing interval register 520. Register 520 is then updated by storing the newly computed first indicated pacing interval in register 520. Based on the first indicated pacing interval stored in register 520, pacing control module 505 deliverscontrol signals to ventricular therapy circuit 320 for delivering therapy, such as pacing stimuli, at the VRR-indicated ventricular heart rate corresponding to the inverse of the duration of the first indicated pacing interval.
In general terms, for one embodiment, device 105 obtains V-V intervals between successive sensed or evoked ventricular beats. Device 105 computes a new first indicated pacing interval based at least in part on the duration of the most recentV-V interval and a previous value of the first indicated pacing interval. Device 105 provides pacing therapy delivered at a rate corresponding to the inverse of the duration of the first indicated pacing interval.
FIG. 6 is a signal flow diagram illustrating generally, by way of example, but not by way of limitation, one embodiment of operating filter 515. Upon the occurrence of a sensed or evoked ventricular beat, timer 510 provides filter 515 with theduration of the V-V interval concluded by that beat, which is referred to as the most recent V-V interval (VV.sub.n). Filter 515 also receives the previous value of the first indicated pacing interval (T.sub.n-1) stored in register 520. The most recentV-V interval VV.sub.n and the previous value of the first indicated pacing interval T.sub.n-1 are each scaled by respective constants A and B, and then summed to obtain a new value of the first indicated pacing interval (T.sub.n), which is stored inregister 520 and provided to pacing control module 505. In one embodiment, the coefficients A and B are different values, and are either programmable, variable, or constant.
If no ventricular beat is sensed during the new first indicated pacing interval T.sub.n, which is measured as the time from the occurrence of the ventricular beat concluding the most recent V-V interval VV.sub.n, then pacing control module 505instructs ventricular therapy circuit 320 to deliver a ventricular pacing pulse upon the expiration of the new first indicated pacing interval T.sub.n. In one embodiment, operation of the filter is described by T.sub.n=AVV.sub.n+BT.sub.n-1, where A andB are coefficients (also referred to as "weights"), VV.sub.n is the most recent V-V interval duration, and T.sub.n-1 is the previous value of the first indicated pacing interval.
Initialization of filter 515 includes seeding the filter by storing, in register 520, an initial interval value. In one embodiment, register 520 is initialized to an interval value corresponding to a lower rate limit (LRL), i.e., a minimum rateat which pacing pulses are delivered by device 105. Register 520 could alternatively be initialized with any other suitable value.
In one embodiment, operation of filter 515 is based on whether the beat concluding the most recent V-V interval VV.sub.n is a sensed/intrinsic beat or a paced/evoked beat. In this embodiment, the pacing control module 505, which controls thetiming and delivery of pacing pulses, provides an input to filter 515 that indicates whether the most recent V-V interval VV.sub.n was concluded by an evoked beat initiated by a pacing stimulus delivered by device 105, or was concluded by an intrinsicbeat sensed by ventricular sensing circuit 310.
In general terms, if the most recent V-V interval VV.sub.n is concluded by a sensed/intrinsic beat, then filter 515 provides a new first indicated pacing interval T.sub.n that is adjusted from the value of the previous first indicated pacinginterval T.sub.n-1 such as, for example, decreased by an amount that is based at least partially on the duration of the most recent V-V interval VV.sub.n and on the duration of the previous value of the first indicated pacing interval T.sub.n-1. If,however, the most recent V-V interval VV.sub.n is concluded by a paced/evoked beat, then filter 515 provides a new first indicated pacing interval T.sub.n that is increased from the value of the previous first indicated pacing interval T.sub.n-1, suchas, for example, by an amount that is based at least partially on the duration of the most recent V-V interval VV.sub.n and on the duration of the previous value of the first indicated pacing interval T.sub.n-1. If no ventricular beat is sensed duringthe new first indicated pacing interval T.sub.n, which is measured as the time from the occurrence of the ventricular beat concluding the most recent V-V interval VV.sub.n, then pacing control module 505 instructs ventricular therapy circuit 320 todeliver a ventricular pacing pulse upon the expiration of the new first indicated pacing interval T.sub.n.
FIG. 7 is a signal flow diagram, illustrating generally, by way of example, but not by way of limitation, another conceptualization of operating filter 515, with certain differences from FIG. 6 more particularly described below. In thisembodiment, the pacing control module 505, which controls the timing and delivery of pacing pulses, provides an input to filter 515 that indicates whether the most recent V-V interval VV.sub.n was concluded by an evoked beat initiated by a pacingstimulus delivered by device 105, or was concluded by an intrinsic beat sensed by ventricular sensing circuit 310.
If the most recent V-V interval VV.sub.n was concluded by an intrinsic beat, then the most recent V-V interval VV.sub.n and the previous value of the first indicated pacing interval T.sub.n-1 are each scaled by respective constants A and B, andthen summed to obtain the new value of the first indicated pacing interval T.sub.n, which is stored in register 520 and provided to pacing control module 505. Alternatively, if the most recent V-V interval VV.sub.n was concluded by a evoked/paced beat,then the most recent V-V interval VV.sub.n and the previous value of the first indicated pacing interval T.sub.n-1 are each scaled by respective constants C and D, and then summed to obtain the new value of the first indicated pacing interval T.sub.n,which is stored in register 520 and provided to pacing control module 505. In one embodiment, the coefficients C and D are different from each other, and are either programmable, variable, or constant. In a further embodiment, the coefficient C is adifferent value from the coefficient A, and/or the coefficient D is a different value than the coefficient B, and these coefficients are either programmable, variable, or constant. In another embodiment, the coefficient D is the same value as thecoefficient B.
In one embodiment, operation of filter 515 is described by T.sub.n=AVV.sub.n+BT.sub.n-1, if VV.sub.n is concluded by an intrinsic beat, and is described by T.sub.n=CVV.sub.n+DT.sub.n-1, if VV.sub.n is concluded by a paced beat, where A, B, C andD are coefficients (also referred to as "weights"), VV.sub.n is the most recent V-V interval duration, T.sub.n is the new value of the first indicated pacing interval, and T.sub.n-1 is the previous value of the first indicated pacing interval. If noventricular beat is sensed during the new first indicated pacing interval T.sub.n, which is measured as the time from the occurrence of the ventricular beat concluding the most recent V-V interval VV.sub.n, then pacing control module 505 instructsventricular therapy circuit 320 to deliver a ventricular pacing pulse upon the expiration of the new first indicated pacing interval T.sub.n.
In another embodiment, these coefficients can be more particularly described using an intrinsic coefficient (a), a paced coefficient (b), and a weighting coefficient (w). In one such embodiment, A=aw, B=(1-w), C=bw, and D=(1-w). In oneexample, operation of the filter 515 is described by T.sub.n=awVV.sub.n+(1-w)T.sub.n-1/, if VV.sub.n is concluded by an intrinsic beat, otherwise is described by T.sub.n=bwVV.sub.n+(1-w)T.sub.n-1, if VV.sub.n is concluded by a paced beat, as illustratedgenerally, by way of example, but not by way of limitation, in the signal flow graph of FIG. 8. If no ventricular beat is sensed during the new first indicated pacing interval T.sub.n, which is measured as the time from the occurrence of the ventricularbeat concluding the most recent V-V interval VV.sub.n, then pacing control module 505 instructs ventricular therapy circuit 320 to deliver a ventricular pacing pulse upon the expiration of the new first indicated pacing interval T.sub.n. In oneembodiment, the coefficients a and b are different from each other, and are either programmable, variable, or constant.
The above-described parameters (e.g., A, B, C, D, a, b, w) are stated in terms of time intervals (e.g., VV.sub.n, T.sub.n, T.sub.n-1). However, an alternate system may produce results in terms of rate, rather than time intervals, withoutdeparting from the present method and apparatus. In one embodiment, weighting coefficient w, intrinsic coefficient a, and paced coefficient b, are variables. Different selections of w, a, and b, will result in different operation of the present methodand apparatus. For example, as w increases the weighting effect of the most recent V-V interval VV.sub.n increases and the weighting effect of the previous first indicated pacing rate T.sub.n-1 decreases. In one embodiment, w= 1/16=0.0625. In anotherembodiment, w= 1/32. Another possible range for w is from w=1/2 to w= 1/1024. A further possible range for w is from w.apprxeq.0 to w.apprxeq.1. Other values of w, which need not include division by powers of two, may be substituted without departingfrom the present method and apparatus.
In one embodiment, intrinsic coefficient a, is selected to be greater than 0.5, or to be greater than 1.0. In one example, the intrinsic coefficient a is selected to be lesser in value than the pacing coefficient b. In one example,a.apprxeq.1.1 and b.apprxeq.1.2. In another embodiment a=0.9 and b=1.1. One possible range for a is from a=0.5 to a=2.0, and for b is from b=1.0 to b=3.0. The coefficients may vary without departing from the present method and apparatus.
In one embodiment, for b>1 and for substantially regular V-V intervals, filter 515 provides a new first indicated pacing interval T.sub.n that is at least slightly longer than the expected intrinsic V-V interval being measured by timer 515. Thus, if the intrinsic V-V interval being timed is consistent with the duration of previously received V-V intervals, then filter 515 avoids triggering a pacing stimulus. In such a case, a pacing pulse is delivered only if the presently timed V-Vinterval becomes longer than the previous substantially constant V-V intervals. In general terms, filter 515 operates so that pacing pulses are typically inhibited if the ventricular rate is substantially constant. However, if the measured V-Vintervals become irregular, then filter 515 operates, over a period of one or several such V-V intervals, to shorten the first indicated pacing interval T.sub.n so that pacing stimuli are being delivered.
According to one aspect of the invention, it is believed that if the irregular V-V intervals are caused by a conducted atrial tachyarrhythmia, then pacing the ventricle will regularize the ventricular heart rate by establishing retrogradeconduction from the ventricle. This, in turn, blocks forward conduction of atrial signals through the atrioventricular (A-V) node. As a result, irregular atrial signals do not trigger resulting irregular ventricular contractions. According to anotheraspect of the invention, however, this method and apparatus will not introduce pacing pulses until the heartbeat becomes irregular. Therefore, the heart is assured to pace at its intrinsic rate when regular ventricular contractions are sensed.
FIG. 9 is a schematic diagram illustrating generally, by way of example, but not by way of limitation, another conceptualization of portions of controller 325, with certain differences from FIG. 5 more particularly described below. In FIG. 9,controller 325 receives from sensor 330 a signal including information from which a physiologically desired heart rate (e.g., based on the patient's activity, respiration, or any other suitable indicator of metabolic need) can be derived. The sensorsignal is digitized by an A/D converter 900. The digitized signal is processed by a sensor rate module 905, which computes a desired heart rate that is expressed in terms of a second indicated pacing interval stored in register 910.
Pacing control module 505 delivers a control signal, which directs ventricular therapy circuit 320 to deliver a pacing pulse, based on either (or both) of the first or second indicated pacing intervals, stored in registers 520 and 910,respectively, or both. In one embodiment, pacing control module 505 includes a selection module 915 that selects between the new first indicated pacing interval T.sub.n and the sensor-based second indicated pacing interval.
In one embodiment, selection module 915 selects the shorter of the first and second indicated pacing intervals as the selected indicated pacing interval S.sub.n. If no ventricular beat is sensed during the selected indicated pacing intervalS.sub.n, which is measured as the time from the occurrence of the ventricular beat concluding the most recent V-V interval VV.sub.n, then pacing control module 505 instructs ventricular therapy circuit 320 to deliver a ventricular pacing pulse upon theexpiration of the selected indicated pacing interval S.sub.n.
In general terms, for this embodiment, the ventricle is paced at the higher of the sensor indicated rate and the VRR indicated rate. If, for example, the patient is resting, such that the sensor indicated rate is lower than the patient'sintrinsic rate, and the patient's intrinsic rate is substantially constant, then the intrinsic rate is higher than the VRR indicated rate. As a result, pacing pulses generally will not be delivered. But if, for example, the patient is resting, but withan atrial tachyarrhythmia that induces irregular ventricular contractions, then pacing pulses generally will be delivered at the VRR indicated rate. In another example, if the patient is active, such that the sensor indicated rate is higher than the VRRindicated rate, then pacing pulses generally will be delivered at the sensor indicated rate. In an alternative embodiment, the pacing rate is determined by blending the sensor indicated rate and the VRR indicated rate, rather than by selecting thehigher of these two indicated rates (i.e., the shorter of the first and second indicated pacing intervals).
In another embodiment, selection module 915 provides a selected indicated pacing interval S.sub.n based on a blending of both the first and second indicated pacing intervals. In one such example, selection module 915 applies predetermined orother weights to the first and second indicated pacing intervals to compute the selected pacing interval S.sub.n.
FIG. 10 is a schematic diagram illustrating generally, by way of example, but not by way of limitation, another conceptualization of portions of controller 325, with certain differences from FIG. 9 more particularly described below. In FIG. 10,controller 325 includes an atrial tachyarrhythmia (AT) detection module 1000 that receives a signal from atrial sensing circuit 305. The received signal includes information about atrial events, from which AT detection module 1000 determines thepresence or absence of one or more atrial tachyarrhythmias, such as atrial fibrillation.
In one embodiment, AT detection module 1000 provides a control signal, to pacing control module 505, that indicates the presence or absence of an atrial tachyarrhythmia, such as atrial fibrillation. In one embodiment, selection module 915selects between the first and second indicated pacing intervals as illustrated, by way of example, but not by way of limitation, in Table 1.
TABLE-US-00001 TABLE 1 Example Selection Based on AT Detection, 1st Indicated Pacing Interval, and 2nd Indicated Pacing Interval 1st Indicated Pacing 1st Indicated Pacing Interval <2nd Indicated Interval .gtoreq.2nd Indicated AT Present?Pacing Interval ? Pacing Interval ? Yes, AT S.sub.n .rarw. 1st Indicated Pacing S.sub.n .rarw. 2nd Indicated Pacing Present Interval (i.e., VRR) Interval (e.g., Sensor) No, AT not S.sub.n .rarw. 2nd Indicated Pacing S.sub.n .rarw. 2nd IndicatedPacing Present Interval (e.g., Sensor) Interval (e.g., Sensor)
In this embodiment, if an atrial tachyarrhythmia is present and the first indicated pacing interval is shorter than the second indicated pacing interval, then selection module 915 selects the first indicated pacing interval, which is based onthe VRR techniques described above, as the selected indicated pacing interval S.sub.n. Otherwise, selection module 915 selects the second indicated pacing interval, which in one embodiment is based on the sensor indications, as the selected indicatedpacing interval S.sub.n. As discussed above, if no ventricular beat is sensed during the selected indicated pacing interval S.sub.n, which is measured as the time from the occurrence of the ventricular beat concluding the most recent V-V intervalVV.sub.n, then pacing control module 505 instructs ventricular therapy circuit 320 to deliver a ventricular pacing pulse upon the expiration of the selected indicated pacing interval S.sub.n.
Stated differently, for this embodiment, the ventricle is paced at the VRR indicated rate only if an atrial tachyarrhythmia, such as atrial fibrillation, is present and the VRR indicated rate exceeds the sensor indicated rate. Otherwise theventricle is paced at the sensor indicated rate. If, for example, the patient is resting, such that the sensor indicated rate is lower than the patient's intrinsic rate, and no atrial tachyarrhythmia is present, then the device will sense the intrinsicrate or will deliver ventricular paces at the lower rate limit. But if, for example, the patient is resting, but with an atrial tachyarrhythmia that induces irregular ventricular contractions, then pacing pulses generally will be delivered at the VRRindicated rate. In another example, if the patient is active, such that the sensor indicated rate is higher than the VRR indicated rate, then pacing pulses generally will be delivered at the sensor indicated rate, whether or not atrial tachyarrhythmiais present. As an alternative to the selection described with respect to Table 1, selection module 915 provides a fixed or variable weighting or blending of both the sensor-indicated rate and VRR indicated rate, such that pacing pulses are deliveredbased on the blended rate.
The second indicated pacing interval need not be based on sensor indications. In one embodiment, for example, the second indicated pacing interval tracks the sensed atrial heart rate when no atrial tachyarrhythmia is present. In thisembodiment, selection module 915 performs a mode-switching function in which the first indicated pacing interval is used whenever atrial tachyarrhythmia is present and the second indicated pacing interval (e.g., atrial-tracking) is used when no atrialtachyarrhythmia is present.
In another embodiment, heart rate/interval is used as a trigger to turn on/off use of the first indicated pacing interval (e.g., the VRR indicated pacing interval). In one example, pacing therapy is based on the first indicated pacing intervalif the first indicated pacing interval is longer than a first predetermined value, and pacing therapy is substantially independent of the first indicated pacing interval if the first indicated pacing interval is shorter than the first predeterminedvalue. In this example, the VRR indicated pacing interval is used at low heart rates, but not at fast heart rates.
FIG. 11 is a graph illustrating generally, by way of example, but not by way of limitation, one embodiment of a VRR indicated rate for successive ventricular heart beats for one mode of operating filter 515. As discussed above, the VRRindicated rate is simply the frequency, between ventricular heart beats, associated with the first indicated pacing interval. Stated differently, the VRR indicated rate is the inverse of the duration of the first indicated pacing interval. If pacing isbased solely on the VRR indicated rate, pacing control module 505 directs ventricular therapy circuit 320 to issue a pacing pulse after the time since the last ventricular beat equals or exceeds the first indicated pacing interval. However, as describedabove, in certain embodiments, pacing control module 505 directs ventricular therapy circuit 320 to issue a pacing pulse based on factors other than the VRR indicated rate such as for, example, based on the sensor indicated rate.
In the example illustrated in FIG. 11, a first sensed intrinsic ventricular beat, indicated by an "S" was detected just before expiration of the first indicated pacing interval ("VRR indicated pacing interval") T.sub.0, as computed based on aprevious ventricular beat. In one embodiment, the new VRR indicated pacing interval T.sub.1 is computed based on the duration of most recent V-V interval VV.sub.1 and a previous value of the VRR indicated pacing interval T.sub.0, as discussed above. Inthis example, the new VRR indicated pacing interval T.sub.1 corresponds to a lower rate limit (LRL) time interval. In one embodiment, the allowable range of the VRR indicated pacing interval is limited so that the VRR indicated pacing interval does notexceed the duration of the LRL time interval, and so that the VRR indicated pacing interval is not shorter than the duration of an upper rate limit (URL) time interval.
The second ventricular beat is also sensed, just before expiration of the VRR indicated pacing interval T.sub.1. In one embodiment, the new VRR indicated pacing interval T.sub.2 is computed based on the duration of most recent V-V intervalVV.sub.2 and a previous value of the VRR indicated pacing interval, T.sub.1, as discussed above. The first and second ventricular beats represent a stable intrinsic rhythm, for which no pacing is delivered because the VRR indicated pacing interval is ata lower rate than the sensed intrinsic ventricular beats.
The third, fourth, and fifth ventricular beats represent the onset of atrial fibrillation, resulting in erratic ventricular rates. The third ventricular beat is sensed well before expiration of the VRR indicated pacing interval T.sub.z, suchthat no pacing pulse is issued. For the sensed third ventricular beat, filter 515 computes the new VRR indicated pacing interval T.sub.3 as being shorter in duration relative to the previous VRR indicated pacing interval T.sub.2.
The fourth ventricular beat is similarly sensed well before expiration of the VRR indicated pacing interval T.sub.3, such that no pacing pulse is issued. For the sensed fourth ventricular beat, filter 515 computes the new VRR indicated pacinginterval T.sub.4 as being shorter in duration relative to the previous VRR indicated pacing interval T.sub.3.
The fifth ventricular beat is sensed before expiration of the VRR indicated pacing interval T.sub.4, such that no pacing pulse is issued. For the sensed fifth ventricular beat, filter 515 computes the new VRR indicated pacing interval T.sub.5as being shorter in duration relative to the previous VRR indicated pacing interval T.sub.4.
The sixth, seventh, and eighth ventricular beats indicate regularization of the ventricular rate using the pacing techniques described above. No ventricular beat is sensed during the VRR indicated pacing interval T.sub.5, so a pacing pulse isissued to evoke the sixth ventricular beat. A new VRR indicated pacing interval T.sub.6 is computed as being increased in duration relative to the previous VRR indicated pacing interval T.sub.5, lowering the VRR indicated rate. Similarly, noventricular beat is sensed during the VRR indicated pacing interval.
The ninth ventricular beat represents another erratic ventricular beat resulting from the atrial fibrillation episode. The ninth ventricular beat is sensed before expiration of the VRR indicated pacing interval T.sub.8. As a result, a shorternew VRR indicated pacing interval T.sub.9 is computed.
The tenth and eleventh ventricular beats illustrate further regularization of the ventricular rate using the pacing techniques described above. No ventricular beat is sensed during the VRR indicated pacing interval T.sub.9, so a pacing pulse isissued to evoke the tenth ventricular beat. A new VRR indicated pacing interval T.sub.10 is computed as being increased in duration relative to the previous VRR indicated pacing interval T.sub.9, lowering the VRR indicated rate. Similarly, noventricular beat is sensed during the VRR indicated pacing interval T.sub.10, so a pacing pulse is issued to evoke the tenth ventricular beat. A new VRR indicated pacing interval T.sub.11 is compute as being increased in duration relative to theprevious VRR indicated pacing interval T.sub.10, lowering the VRR indicated rate.
The twelfth, thirteenth, fourteenth, and fifteenth ventricular beats illustrate resumption of a stable intrinsic rhythm after termination of the atrial fibrillation episode. For such a stable rate, the VRR indicated rate proceeds asymptoticallytoward a "floor value" that tracks, but remains below, the intrinsic rate. This allows the intrinsic heart signals to control heart rate when such intrinsic heart signals provide a stable rhythm. As a result, when the patient's intrinsic rate isconstant, paces will be withheld, allowing the patient's intrinsic heart rhythm to continue. If the patient's heart rate includes some variability, and the VRR indicated floor value is close to the mean intrinsic heart rate, then occasional paced beatswill occur. Such pace beats will gradually lengthen the VRR indicated pacing interval, thereby allowing subsequent intrinsic behavior when the patient's heart rate becomes substantially constant.
The intrinsic coefficient a of filter 515 controls the "attack slope" of the VRR indicated heart rate as the VRR indicated heart rate increases because of sensed intrinsic beats. The paced coefficient b of filter 515 controls the "decay slope"of the VRR indicated heart rate as the VRR indicated heart rate decreases during periods of paced beats. In one embodiment, in which a>1.0 and b>1.0, decreasing the value of a toward 1.0 increases the attack slope such that the VRR indicated rateincreases faster in response to sensed intrinsic beats, while decreasing the value of b toward 1.0 decreases the decay slope such that the VRR indicated rate decreases more slowly during periods of paced beats. Conversely, for a>1.0 and b>1.0,increasing the value of a from 1.0 decreases the attack slope such that the VRR indicated rate increases more slowly in response to sensed intrinsic beats, while increasing the value of b from 1.0 increases the decay slope such that the VRR-indicatedrate decreases more quickly during periods of paced beats.
In one embodiment, for a>1.0 and b>1.0, decreasing both a and b toward 1.0 increases VRR indicated rate during periods of sensed intrinsic activity so that the VRR indicated rate is closer to the mean intrinsic rate. Because the VRRindicated rate is closer to the mean intrinsic rate, variability in the intrinsic heart rate is more likely to trigger paces at the VRR indicated rate. On the other hand, for a>1.0 and b>1.0, increasing both a and b from 1.0 decreases the VRRindicated rate during periods of sensed intrinsic activity so that the VRR indicated rate is farther beneath the mean intrinsic rate. Because the VRR indicated rate is farther beneath the mean intrinsic rate, the same variability in the intrinsic heartrate becomes less likely to trigger paces at the VRR indicated rate.
In one embodiment, these coefficients are programmable by the user, such as by using remote programmer 125. In another embodiment, the user selects a desired performance parameter (e.g., desired degree of rate regularization, desired attackslope, desired decay slope, etc.) from a corresponding range of possible values, and device 105 automatically selects the appropriate combination of coefficients of filter 515 to provide a filter setting that corresponds to the selected user-programmedperformance parameter, as illustrated generally by Table 2. Other levels of programmability or different combinations of coefficients may also be used.
TABLE-US-00002 TABLE 2 Example of Automatic Selection of Aspects of Filter Setting Based on a User-Programmable Performance Parameter. User-Programmable Performance Parameter Intrinsic Coefficient a Paced Coefficient b 1 (Less Rate 2.0 3.0Regularization) 2 1.8 2.6 3 1.6 2.2 4 1.4 1.8 5 1.2 1.4 6 (More Rate 1.0 1.0 Regularization)
FIG. 12 is a graph illustrating generally, by way of example, but not by way of limitation, one embodiment of selecting between more than one indicated pacing interval. FIG. 12 is similar to FIG. 11 in some respects, but FIG. 12 includes asecond indicated pacing interval. In one embodiment, the first indicated pacing interval is the VRR indicated pacing interval, described above, and the second indicated pacing interval is a sensor indicated pacing interval, from an accelerometer, minuteventilation, or other indication of the patient's physiological need for increased cardiac output.
In one embodiment, a selected indicated pacing interval is based on the shorter of the first and second indicated pacing intervals. Stated differently, device 105 provides pacing pulses at the higher indicated pacing rate. In the exampleillustrated in FIG. 12, first and second beats and the twelfth through fifteenth beats are paced at the sensor indicated rate, because it is higher than the VRR indicated rate and the intrinsic rate. The third, fourth, fifth, and ninth beats are sensedintrinsic beats that are sensed during the shorter of either of the VRR and sensor indicated pacing intervals. The sixth through eighth beats and tenth and eleventh beats are paced at the VRR indicated rate, because it is higher than the sensorindicated rate. Also, for these beats, no intrinsic beats are sensed during the VRR indicated intervals. In one embodiment, the above-described equations for filter 515 operate to increase the VRR indicated rate toward the sensor-indicated rate whenthe sensor indicated rate is greater than the VRR indicated rate, as illustrated by first through third and twelfth through fifteenth beats in FIG. 12. In an alternate embodiment, however, T.sub.n=bwVV.sub.n+(1-w)T.sub.n-1, if VV.sub.n is concluded by aVRR indicated paced beat, and T.sub.n=T.sub.n-1 if VV.sub.n is concluded by a sensor indicated paced beat, thereby leaving the VRR indicated rate unchanged for sensor indicated paced beats.
In this embodiment, the ranges of both the sensor indicated rate and the VRR indicated rate are limited so that they do not extend to rates higher than the URL or to rates lower than the LRL. In one embodiment, the LRL and the URL areprogrammable by the user, such as by using remote programmer 125.
In a further embodiment, the selected indicated pacing interval is based on the shorter of the first and second indicated pacing intervals only if an atrial tachyarrhythmia, such as atrial fibrillation, is present. Otherwise, the secondindicated pacing interval is used, as described above.
FIG. 13 is a graph illustrating generally, by way of example, but not by way of limitation, another illustrative example of heart rate vs. time according to a spreadsheet simulation of the behavior of the above-described VRR algorithm. In FIG.13, the VRR algorithm is turned off until time 130. Stable intrinsic lower rate behavior is modeled for times between 0 and 10 seconds. Erratic intrinsic ventricular rates, such as would result from atrial tachyarrhythmias including atrialfibrillation, are modeled during times between 10 seconds and 130 seconds. At time 130 seconds, the VRR algorithm is turned on. While some erratic intrinsic beats are subsequently observed, the VRR algorithm provides pacing that is expected tosubstantially stabilize the heart rate, as illustrated in FIG. 13. The VRR indicated pacing rate gradually decreases until intrinsic beats are sensed, which results in a slight increase in the VRR indicated pacing rate. Thus, the VRR algorithm favorsthe patient's intrinsic heart rate when it is stable, and paces at the VRR indicated heart rate when the patient's intrinsic heart rate is unstable. It is noted that FIG. 13 does not represent clinical data, but rather provides a simulation model thatillustrates one example of how the VRR algorithm is expected to operate.
In one embodiment, filter 515 includes variable coefficients such as, for example, coefficients that are a function of heart rate (or its corresponding time interval). In one example, operation of the filter 515 is described byT.sub.n=awVV.sub.n+(1-w)T.sub.n-1, if VV.sub.n is concluded by an intrinsic beat, otherwise is described by T.sub.n=bwVV.sub.n+(1-w)T.sub.n-1, if VV.sub.n is concluded by a paced beat, where at least one of a and b are linear, piecewise linear, ornonlinear functions of one or more previous V-V intervals such as, for example, the most recent V-V interval, VV.sub.n.
FIG. 14 is a graph illustrating generally, by way of example, but not by way of limitation, one embodiment of using at least one of coefficients a and b as a function of one or more previous V-V intervals such as, for example, the most recentV-V interval, VV.sub.n. In one such example, a is less than 1.0 when VV.sub.n is at or near the lower rate limit (e.g., 1000 millisecond interval or 60 beats/minute), and a is greater than 1.0 when VV.sub.n is at or near the upper rate limit (e.g., 500millisecond interval or 120 beats/minute). For a constant b, using a smaller value of a at lower rates will increase the pacing rate more quickly for sensed events; using a larger value of a at higher rates increases the pacing rate more slowly forsensed events. In another example, b is close to 1.0 when VV.sub.n is at or near the lower rate limit, and b is greater than 1.0 when VV.sub.n is at or near the upper rate limit. For a constant a, using a smaller value of b at lower rates will decreasethe pacing rate more slowly for paced events; using a larger value of b at higher rates decreases the pacing rate more quickly for paced events.
In one embodiment, the present cardiac rhythm management system utilizes the VRR filter 515 for providing biventricular pacing coordination therapy in both right and left ventricles, thereby coordinating the contractions of the right and leftventricles for more efficient pumping. The VRR filter 515 controls the timing of delivery of biventricular pacing pulses. Filter 515 provides a first indicated pacing rate that is independent of (i.e., does not track) the intrinsic atrial rate. Thefirst indicated pacing rate is generally above the mean intrinsic ventricular rate so that it can provide substantially continuous pacing therapy. This is advantageous because, among other things, either or both of the intrinsic atrial or intrinsicventricular heart rates may be extremely irregular, such as during atrial tachyarrhythmias. The VRR techniques described above with respect to FIGS. 1-14 promote intrinsic ventricular beats when the ventricular heart rate is substantially constant. Incontrast to such Ventricular Rate Regularization that promotes intrinsic activity, biventricular coordination therapy typically uses Ventricular Rate Regulation that provides nearly continuous (i.e., to the desired degree) biventricular pacing when theventricular rate is substantially constant. One selection of coefficients for filter 515 for obtaining nearly continuous pacing is described below.
FIG. 15 is a schematic drawing, similar to FIG. 2, illustrating generally by way of example, but not by way of limitation, one embodiment of a cardiac rhythm management device 105 coupled by leads 110A-C to a heart 115. In one such embodiment,system 100 provides biventricular coordination therapy to coordinate right ventricular and left ventricular contractions, such as for congestive heart failure patients. FIG. 15 includes a left ventricular lead 110C, inserted through coronary sinus 220and into the great cardiac vein so that its electrodes, which include electrodes 1500 and 1505, are associated with left ventricle 205B for sensing intrinsic heart signals and providing one or more of coordination paces or defibrillation shocks.
FIG. 16 is a schematic drawing, similar to FIG. 3, illustrating generally by way of example, but not by way of limitation, one embodiment of portions of a cardiac rhythm management device 105, in which the left ventricular lead is coupled bylead 110C to a left ventricular sensing circuit 1600 and a left ventricular therapy circuit 1605, each of which are, in turn, coupled by node/bus 327 to controller 325. This embodiment also includes an atrial therapy circuit 1610, and a rightventricular lead 110B coupling right ventricle 205A to right ventricular sensing circuit 310 and right ventricular therapy circuit 320, each of which are, in turn, coupled by node/bus 327 to controller 325.
FIG. 17 is a schematic drawing, similar to FIG. 5, illustrating generally by way of example, but not by way of limitation, portions of one conceptual embodiment of controller 325. In this embodiment, ventricular event module 500 receives inputsignals from right ventricular sensing circuit 310 and left ventricular sensing circuit 1600. Pacing control module 505 provides control signals to right ventricular therapy circuit 320 and left ventricular therapy circuit 1605. Operation of filter 515is similar to the above description accompanying FIGS. 5-14, with certain differences discussed below, thereby allowing device 105 to provide biventricular coordination therapy at a VRR-indicated rate, a sensor-indicated rate, or a combination thereof.
In one embodiment, ventricular event module 500 detects sensed and paced ventricular beats from both right ventricular sensing circuit 310 and left ventricular sensing circuit 1600. An interval between successive ventricular events, referred toas a V-V interval, is recorded by a first timer, such as V-V interval timer 510. Ventricular event module 500 selects the particular ventricular events initiating and concluding the V-V interval timed by V-V interval timer 510. In a first mode ofoperation, the V-V interval is initiated by a right ventricular beat (paced or sensed), and the V-V interval is then concluded by the next right ventricular beat (paced or sensed). In a second mode of operation, the V-V interval is initiated by a leftventricular beat (paced or sensed), and the V-V interval is then concluded by the next left ventricular beat (paced or sensed). In a third mode of operation, the V-V interval is initiated by either a right or left ventricular beat, and the V-V intervalis then concluded by the next right or left ventricular beat that occurs after expiration of a refractory period of approximately between 130 milliseconds and 500 milliseconds (e.g., 150 milliseconds). Left or right ventricular beats occurring duringthe refractory period are ignored. Using the refractory period ensures that the beat concluding the V-V interval is associated with a subsequent ventricular contraction, rather than a depolarization associated with the same ventricular contraction, inwhich the depolarization is merely sensed in the opposite ventricle from the initiating beat. Such a refractory period can also be used in conjunction with the first mode (V-V interval initiated and concluded by right ventricular beats) or the secondmode (V-V interval initiated and concluded by left ventricular beats).
Filter 515 computes a "first indicated pacing interval," i.e., one indication of a desired time interval between ventricular events or, stated differently, a desired ventricular heart rate. Based on the first indicated pacing interval stored inregister 520, pacing control module 505 delivers control signals to one or more of therapy circuits 320 and 340 for delivering therapy, such as biventricular pacing coordination stimuli to one or more of right ventricle 205A and left ventricle 205B, atthe VRR indicated ventricular heart rate corresponding to the inverse of the duration of the first indicated pacing interval.
Ventricular event module 500 also includes an output node/bus 1700 coupled to pacing control module 505. Ventricular event module 500 communicates to pacing control module 505 information about the occurrence (e.g., timing, origin, etc.) ofright and left ventricular sensed beats, so that pacing control module 505 can issue biventricular coordination therapy to obtain coordinated right and left ventricular contractions. In one embodiment, a sensed right ventricular contraction triggers animmediate or very slightly delayed left ventricular pacing pulse, either alone, or in conjunction with a right ventricular pacing pulse. Similarly, a sensed left ventricular contraction triggers an immediate or very slightly delayed right ventricularpacing pulse, either alone or in conjunction with a left ventricular pacing pulse. This ensures that contractions of the right and left ventricles are coordinated to provide more efficient pumping of blood by the heart 115. In one embodiment, thecontroller illustrated in FIG. 17 includes a sensor channel, as discussed above with respect to FIG. 9. In this embodiment, device 105 provides biventricular coordination therapy at a VRR-indicated rate, a sensor-indicated rate, or a combinationthereof.
In one embodiment, the coefficients of filter 515 are programmable by the user, such as by using remote programmer 125, as described above, in order to obtain a desired degree of pacing vs. sensing. In another embodiment, the user selects adesired performance parameter (e.g., desired degree of pacing vs. sensing, etc.) from a corresponding range of possible values, and device 105 automatically selects the appropriate combination of coefficients of filter 515 to provide a filter settingthat corresponds to the selected user-programmed performance parameter, as illustrated generally by Table 3. Other levels of programmability or different combinations of coefficients may also be used.
TABLE-US-00003 TABLE 3 Example of Automatic Selection of Aspects of Filter Setting Based on a User-Programmable Performance Parameter Such as For Providing Biventricular Coordination Therapy. User- Programmable Performance Intrinsic PacedParameter Coefficient a Coefficient b 1 (More Pacing) 0.6 1.05 2 0.7 1.2 3 0.8 1.3 4 0.9 1.4 5 (Less Pacing) 1.0 1.5
In a further embodiment, device 105 uses a mapping, such as illustrated in Table 3, in a feedback control loop to automatically select the "performance parameter" of Table 3 and corresponding coefficients. The user programs a mean pacingfrequency goal. Device 105 measures the mean pacing frequency over a predetermined period of time or predetermined number of V-V intervals. The measured mean pacing is compared to the mean pacing frequency goal. If the measured mean pacing frequencyis higher than the goal mean pacing frequency, the performance parameter in Table 3 is incremented/decremented toward less pacing. Conversely, if the measured mean pacing frequency is lower than the goal mean pacing frequency, the performance parameterin Table 3 is incremented/decremented toward more pacing. In a further embodiment, the measured mean pacing frequency is compared to values that are slightly offset about the goal mean pacing frequency (e.g., goal mean pacing frequency +/-.DELTA.) toprovide a band of acceptable measured mean pacing frequencies within which the performance parameter is not switched.
The preceding embodiment illustrated techniques of providing rate regulation for delivering biventricular coordination therapy to congestive heart failure patients. Such techniques are particularly advantageous in the presence of atrialtachyarrhythmias, such as atrial fibrillation. When atrial tachyarrhythmias are present, atrial rate tracking would result in too-fast and irregular biventricular coordination therapy. Because atrial tachyarrhythmias often induce irregular ventricularcardiac cycle lengths, ventricular tracking would also produce erratic results if the above-described VRR techniques are not used.
Where no atrial tachyarrhythmias are present, however, biventricular coordination therapy based on atrial rate tracking is possible. The above-disclosed techniques are still useful, however, for providing a first indicated timing interval. Inone example, the first indicated timing interval is a filter indicated atrioventricular (AV) delay based on the intrinsic AV delay, i.e., the interval between a sensed P wave and a successively sensed R wave. In this example, biventricular coordinationtherapy is provided based on the tracking of an atrial rate. Each biventricular coordination pacing pulse is delivered after the filter indicated AV delay. The filter indicated AV delay is computed similarly to the VRR techniques described above, withcertain differences described more particularly below.
FIG. 18 is a schematic diagram, similar to FIG. 17, illustrating generally by way of example, but not by way of limitation, another conceptualization of portions of controller 325 used for regulating the AV interval based on a filter indicatedAV delay. In FIG. 18, atrial event module 1800 and ventricular event module 500 provide information about paced or sensed atrial events and paced or sensed ventricular events, respectively, to AV interval timer 1805. AV interval timer 1805 times an AVinterval initiated by an atrial event, and concluded by a ventricular event, such as described above with respect to FIG. 17.
In one example, operation of the filter 515 is described by T.sub.n=awAV.sub.n+(1-w)T.sub.n-1, if AV.sub.n is concluded by an intrinsic beat, otherwise is described by T.sub.n=bwAV.sub.n+(1-w)T.sub.n-1, if AV, is concluded by a paced beat, whereT.sub.n is the newly computed value of the filter indicated AV interval, T.sub.n-1 is the previous value of the filter indicated AV interval, AV.sub.n is the time interval corresponding to the most recent AV delay period, and a, b, and w arecoefficients. In one embodiment, weighting coefficient w, intrinsic coefficient a, and paced coefficient b, are variables. Different selections of w, a, and b, will result in different operation of the present method and apparatus. For example, as wincreases the weighting effect of the most recent A-V interval AV.sub.n increases and the weighting effect of the previous first indicated pacing rate T.sub.n-1 decreases. In one embodiment, w= 1/16=0.0625. In another embodiment, w= 1/32. Anotherpossible range for w is from w=1/2 to w= 1/1024. A further possible range for w is from w.apprxeq.0 to w.apprxeq.1. Other values of w, which need not include division by powers of two, may be substituted without departing from the present method andapparatus.
In one embodiment, intrinsic coefficient a, is selected to be less than (or, alternatively, less than or equal to) 1.0. In one example, the intrinsic coefficient a is selected to be lesser in value than the pacing coefficient b. In oneembodiment, a.apprxeq.0.6 and b.apprxeq.1.5. In another embodiment, a=1.0 and b=1.05. One possible range for a is from a=0.6 to a=1.0, and for b is from b=1.05 to b=1.5. The coefficients may vary without departing from the present method andapparatus.
In one embodiment, these coefficients are programmable by the user, such as by using remote programmer 125. In another embodiment, the user selects a desired performance parameter (e.g., desired degree pacing vs. sensing, desired attack slope,desired decay slope, etc.) from a corresponding range of possible values, and device 105 automatically selects the appropriate combination of coefficients of filter 515 to provide a filter setting that corresponds to the selected user-programmedperformance parameter, as illustrated generally by Table 4. Other levels of programmability or different combinations of coefficients may also be used.
TABLE-US-00004 TABLE 4 Example of Automatic Selection of Aspects of Filter Setting Based on a User-Programmable Performance Parameter, Such as for AV Delay Regulation User- Programmable Performance Intrinsic Paced Parameter Coefficient aCoefficient b 1 (Less Aggressive 1.0 1.05 Attack/Decay) 2 0.9 1.2 3 0.8 1.3 4 0.7 1.4 5 (More Aggressive 0.6 1.5 Attack/Decay)
In a further embodiment, device 105 uses a mapping, such as illustrated in Table 4, in a feedback control loop to automatically select the "performance parameter" and corresponding coefficients. The user programs a mean sense frequency goal. Device 105 measures the mean frequency of sensed ventricular events ("measured mean sense frequency") over a predetermined period of time or predetermined number of A-V intervals, and adjusts the performance parameter and corresponding coefficients todirect the measured mean sense frequency toward the mean sense frequency goal.
The above techniques provide an example in which AV delay is regulated. However, it is understood that these techniques extend to the regulation of any other timing interval. In one embodiment, for example, operation of filter 515 is expressedmore generically as T.sub.n=AEE.sub.n+BT.sub.n-1, if EE.sub.n is concluded by an intrinsic beat, otherwise is described by T.sub.n=CEE.sub.n+DT.sub.n-1, if EE.sub.n is concluded by a paced beat, where T.sub.n is the newly computed value of the indicatedtiming interval, T.sub.n-1 is the previous value of the indicated timing interval, EE.sub.n is the measured timing interval between any two events, and A, B, C, and D are coefficients.
The above-described system provides, among other things, a cardiac rhythm management system including techniques for computing an indicated pacing interval, AV delay, or other timing interval. In one embodiment, a variable indicated pacinginterval is computed based at least in part on an underlying intrinsic heart rate. The indicated pacing interval is used to time the delivery of biventricular coordination therapy even when ventricular heart rates are irregular, such as in the presenceof atrial fibrillation. In another embodiment, a variable filter indicated AV interval is computed based at least in part on an underlying intrinsic AV interval. The indicated AV interval is used to time the delivery of atrial tracking biventricularcoordination therapy when atrial heart rhythms are not arrhythmic. Other indicated timing intervals may be similarly determined. The indicated pacing interval, AV delay, or other timing interval can also be used in combination with a sensor indicatedrate indicator.
It is to be understood that the above description is intended to be illustrative, and not restrictive. Many other embodiments will be apparent to those of skill in the art upon reviewing the above description. The scope of the inventionshould, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.
Polyimide embedded conductor process
Tubular rod for the treatment of the inside surface of a tube
Temperature control device adapted to prevent overheating
Control method for cycloconverter and control apparatus therefor
Orthopedic pillow and method of using it
Human biovibrations method